<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Positive pressure therapy for Ménière's disease or syndrome - van Sonsbeek, S - 2015 | Cochrane Library</title> <meta content="Positive pressure therapy for Ménière's disease or syndrome - van Sonsbeek, S - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008419.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Positive pressure therapy for Ménière's disease or syndrome - van Sonsbeek, S - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008419.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008419.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Positive pressure therapy for Ménière's disease or syndrome" name="citation_title"/> <meta content="Sanne van Sonsbeek" name="citation_author"/> <meta content="Gelre Hospitals" name="citation_author_institution"/> <meta content="sanne.vansonsbeek@gmail.com" name="citation_author_email"/> <meta content="Bas Pullens" name="citation_author"/> <meta content="Erasmus MC ‐ Sophia Children's Hospital" name="citation_author_institution"/> <meta content="Peter Paul van Benthem" name="citation_author"/> <meta content="Gelre Hospitals" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD008419.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/03/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008419.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008419.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008419.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Meniere Disease [*therapy]; Middle Ear Ventilation; Randomized Controlled Trials as Topic; Syndrome; Transtympanic Micropressure Treatment [instrumentation, *methods]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008419.pub2&amp;doi=10.1002/14651858.CD008419.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008419\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008419\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008419.pub2",title:"Positive pressure therapy for M\\u00E9ni\\u00E8re\u0027s disease or syndrome",firstPublishedDate:"Mar 10, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane ENT Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008419.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008419.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008419.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008419.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008419.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008419.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008419.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008419.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008419.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008419.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5258 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008419.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-sec-0107"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-sec-0057"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-sec-0101"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/appendices#CD008419-sec-0112"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/table_n/CD008419StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/table_n/CD008419StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Positive pressure therapy for Ménière's disease or syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/information#CD008419-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sanne van Sonsbeek</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/information#CD008419-cr-0003">Bas Pullens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008419.pub2/information#CD008419-cr-0004">Peter Paul van Benthem</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/information/en#CD008419-sec-0119">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 March 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008419.pub2">https://doi.org/10.1002/14651858.CD008419.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008419-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008419-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008419-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008419-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008419-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008419-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008419-abs-0001" lang="en"> <section id="CD008419-sec-0001"> <h3 class="title" id="CD008419-sec-0001">Background</h3> <p>Ménière's disease is an incapacitating disease in which recurrent attacks of vertigo are accompanied by hearing loss, tinnitus and/or aural fullness, all of which are discontinuous and variable in intensity. A number of different therapies have been identified for patients with this disease, ranging from dietary measures (e.g. a low‐salt diet) and medication (e.g. betahistine (Serc®), diuretics) to extensive surgery (e.g. endolymphatic sac surgery). The Meniett® low‐pressure pulse generator (Medtronic ENT, 1999) is a device that is designed to generate a computer‐controlled sequence of low‐pressure (micro‐pressure) pulses, which are thought to be transmitted to the vestibular system of the inner ear. The pressure pulse passes via a tympanostomy tube (grommet) to the middle ear, and hence to the inner ear via the round and/or oval window. The hypothesis is that these low‐pressure pulses reduce endolymphatic hydrops. </p> </section> <section id="CD008419-sec-0002"> <h3 class="title" id="CD008419-sec-0002">Objectives</h3> <p>To assess the effects of positive pressure therapy (e.g. the Meniett device) on the symptoms of Ménière's disease or syndrome. </p> </section> <section id="CD008419-sec-0003"> <h3 class="title" id="CD008419-sec-0003">Search methods</h3> <p>We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL); PubMed; EMBASE; CINAHL; Web of Science; Cambridge Scientific Abstracts; ICTRP and additional sources for published and unpublished trials. The date of the search was 6 June 2014. </p> </section> <section id="CD008419-sec-0004"> <h3 class="title" id="CD008419-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing positive pressure therapy (using the Meniett or a similar device) with placebo in patients with Ménière's disease. The primary outcome was control of vertigo; secondary outcomes were loss or gain of hearing, severity of tinnitus, perception of aural fullness, functional level, complications or adverse effects, and sick days. </p> </section> <section id="CD008419-sec-0005"> <h3 class="title" id="CD008419-sec-0005">Data collection and analysis</h3> <p>Two authors independently selected studies, assessed risk of bias and extracted data. We contacted authors for additional data. Where possible, we pooled study results using a fixed‐effect, mean difference (MD) meta‐analysis and tested for statistical heterogeneity using both the Chi² test and I² statistic. This was only possible for the secondary outcomes loss or gain of hearing and sick days. We presented results using forest plots with 95% confidence intervals (Cl). </p> </section> <section id="CD008419-sec-0006"> <h3 class="title" id="CD008419-sec-0006">Main results</h3> <p>We included five randomised clinical trials with 265 participants. All trials were prospective, double‐blind, placebo‐controlled randomised controlled trials on the effects of positive pressure therapy on vertigo complaints in Ménière's disease. Overall, the risk of bias varied: three out of five studies were at low risk, one was at unclear risk and one was at high risk of bias. </p> <p><b><i>Control of vertigo</i> </b> </p> <p>For the primary outcome, control of vertigo, it was not possible to pool data due to heterogeneity in the measurement of the outcome measures. In most studies, no significant difference was found between the positive pressure therapy group and the placebo group in vertigo scores or vertigo days. Only one study, at low risk of bias, showed a significant difference in one measure of vertigo control in favour of positive pressure therapy. In this study, the mean visual analogue scale (VAS) score for vertigo after eight weeks of treatment was 25.5 in the positive pressure therapy group and 46.6 in the placebo group (mean difference (MD) ‐21.10, 95% CI ‐35.47 to ‐6.73; scale not stated ‐ presumed to be 0 to 100). </p> <p><b><i>Secondary outcomes</i> </b> </p> <p>For the secondary outcomes, we carried out two pooled analyses. We found statistically significant results for <b><i>loss or gain of hearing</i> </b> . Hearing was 7.38 decibels better in the placebo group compared to the positive pressure therapy group (MD) (95% CI 2.51 to 12.25; two studies, 123 participants). The <b><i>severity of tinnitus</i> </b> and <b><i>perception of aural fullness</i> </b> were either not measured or inadequate data were provided in the included studies. For the secondary outcome <b><i>functional level</i> </b> , it was not possible to perform a pooled analysis. One included study showed less functional impairment in the positive pressure group than the placebo group (AAO‐HNS criteria, one‐ to six‐point scale: MD ‐1.10, 95% CI ‐1.81 to ‐0.39, 40 participants); another study did not show any significant results. In addition to the predefined secondary outcome measures, we included <b><i>sick days</i> </b> as an additional outcome measure, as two studies used this outcome measure and it is a complementary measurement of impairment due to Ménière's disease. We did not find a statistically significant difference in sick days. No <b><i>complications or adverse effects</i> </b> were noted by any study. </p> </section> <section id="CD008419-sec-0007"> <h3 class="title" id="CD008419-sec-0007">Authors' conclusions</h3> <p>There is no evidence, from five included studies, to show that positive pressure therapy is effective for the symptoms of Ménière's disease. There is some moderate quality evidence, from two studies, that hearing levels are worse in patients who use this therapy. The positive pressure therapy device itself is minimally invasive. However, in order to use it, a tympanostomy tube (grommet) needs to be inserted, with the associated risks. These include the risks of anaesthesia, the general risks of any surgery and the specific risks of otorrhoea and tympanosclerosis associated with the insertion of a tympanostomy tube. Notwithstanding these comments, no complications or adverse effects were noted in any of the included studies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008419-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008419-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008419-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008419-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008419-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008419-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008419-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008419-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008419-abs-0004" lang="en"> <h3>Positive pressure therapy for Ménière's disease or syndrome</h3> <p><b>Background</b> </p> <p>Ménière's disease is a disorder of the inner ear, which results in vertigo, hearing loss and tinnitus. When it is secondary to another known inner ear disorder, it is called Ménière's syndrome. A number of different treatments have been used for patients with this disease, ranging from dietary measures (e.g. a low‐salt diet) and medication (e.g. betahistine or diuretics) to extensive surgery. However, Ménière's disease has a fluctuating natural course with remissions and exacerbations, which makes the evaluation of treatments difficult. </p> <p>Positive pressure therapy uses a device (such as the Meniett®) placed in the external ear to generate a sequence of low‐pressure (micro‐pressure) pulses. These pulses are thought to be transmitted to the vestibular system of the inner ear and to influence inner ear pressure. The device has been proposed as a second‐level therapy for Ménière's disease. In order to use the device a patient needs to have a tympanostomy tube (grommet) inserted through their eardrum. </p> <p><b>Study characteristics</b> </p> <p>In this review, we included five randomised controlled trials, with a total of 265 participants. All participants had Ménière's disease and their ages ranged from 19 to 74 years. In all of the studies positive pressure therapy was compared with a placebo device. </p> <p><b>Key results</b> </p> <p>For our primary outcome, control of vertigo, we could not combine the results from the different studies because of differences in the way the outcome was measured. None of the included studies showed significant differences between the active groups and placebo groups in terms of vertigo days. Only one study found significantly lower subjective scores for vertigo in favour of the positive pressure therapy group when compared to the placebo group. </p> <p>When we combined the results from two studies we found that after treatment patients in the placebo group had better hearing levels compared to those in the positive pressure therapy group. The severity of tinnitus and perception of aural fullness were either not measured or the included studies did not provide enough information for us to comment on them. We did not find an overall statistically significant result for functional level. We also looked at 'sick days' but we did not find a statistically significant difference between groups in the two studies that measured this. No complications or adverse effects were noted by any study. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, the studies were at varied risk of bias: three out of five studies were at low risk, one was at unclear risk and one was at high risk of bias. The evidence is up to date to June 2014. </p> <p><b>Conclusions</b> </p> <p>In conclusion, this review has not found adequate evidence to prove the effectiveness of positive pressure therapy. Further research is needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008419-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008419-sec-0107"></div> <h3 class="title" id="CD008419-sec-0108">Implications for practice</h3> <section id="CD008419-sec-0108"> <p>There is insufficient evidence to demonstrate the effectiveness of positive pressure therapy for the symptoms of Ménière's disease. No adverse effects were described in the included studies, although in other case series studies middle ear infections, immediate postoperative ear discharge or otorrhoea have been described. </p> <p>The significant results found in this review should be considered inconclusive. Hearing loss overall seems to be greater after using the Meniett device compared to placebo, but separate analyses show opposing results. Analyses of functional level showed opposing results between studies, and neither definite vertigo scores or vertigo days, nor sick days improved. </p> </section> <h3 class="title" id="CD008419-sec-0109">Implications for research</h3> <section id="CD008419-sec-0109"> <p>In order to be able to achieve the primary objective of this review, to determine the effects of positive pressure therapy on the symptoms of Ménière's disease, compared with placebo, further research is needed. Future randomised controlled trials should use the American Academy of Otolaryngology ‐ Head and Neck Surgery (AAO‐HNS) criteria for the diagnosis of Ménière's disease and control of the disease (<a href="./references#CD008419-bbs2-0038" title="MonsellEM . New and revised reporting guidelines from the Committee on Hearing and Equilibrium. American Academy of Otolaryngology ‐ Head and Neck Surgery Foundation, Inc. Otolaryngology ‐ Head and Neck Surgery1995;113(3):176‐8. ">Monsell 1995</a>), use uniform criteria, adequately report study methods and statistics, and have a minimum follow‐up period of two years. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008419-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008419-sec-0029"></div> <div class="table" id="CD008419-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Positive pressure therapy versus placebo for Ménière's disease or syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Positive pressure therapy versus placebo for Ménière's disease or syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with Ménière's disease or syndrome<br/> <b>Settings:</b> ENT departments<br/> <b>Intervention:</b> positive pressure therapy versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Positive pressure therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of days with vertigo in 4 weeks: vertigo scores &gt; 2</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean proportion of days with vertigo in 4 weeks (vertigo scores &gt; 2) in the control groups was<br/> <b>0.11</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean proportion of days with vertigo in 4 weeks (vertigo scores &gt; 2) in the intervention groups was<br/> <b>0.01 lower</b> <br/> (0.08 lower to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cumulative vertigo scores after 4 months</b> <br/> Follow‐up: mean 4 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cumulative vertigo score after 4 months in the control groups was<br/> <b>19.23</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cumulative vertigo score after 4 months in the intervention groups was<br/> <b>3.68 lower</b> <br/> (14.24 lower to 6.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vertigo days in 4 months: vertigo scores &gt; 2</b> <br/> Follow‐up: mean 4 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo days in 4 months (vertigo scores &gt; 2) in the control groups was<br/> <b>5.52</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo days in 4 months (vertigo scores &gt; 2) in the intervention groups was<br/> <b>1.55 lower</b> <br/> (5.4 lower to 2.3 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vertigo frequency in the 8 weeks before and after 4 weeks of treatment</b> <br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo frequency in the 8 weeks before and after 4 weeks of treatment in the control groups was<br/> <b>4.0</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo frequency in the 8 weeks before and after 4 weeks of treatment in the intervention groups was<br/> <b>2.10 lower</b> <br/> (5.25 lower to 1.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VAS scores for vertigo after 8 weeks of treatment</b> <br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score for vertigo after 8 weeks of treatment in the control groups was<br/> <b>46.6</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score for vertigo after 8 weeks of treatment in the intervention groups was<br/> <b>21.1 lower</b> <br/> (35.47 to 6.73 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Loss or gain of hearing in 4 months (dB)</b> </p> <p>Follow‐up: mean 4 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hearing threshold at 0.25 kHz to 1 kHz in 4 months in the control groups was<br/> <b>44.4</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean loss or gain of hearing in 4 months in the intervention groups was<br/> <b>7.38 higher</b> <br/> (2.51 to 12.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cumulative activity score</b> </p> <p>Follow‐up: mean 4 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean activity score after 4 months in the control group was</p> <p><b>20.23</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cumulative activity score in the intervention groups was<br/> <b>7.18 lower</b> <br/> (17.68 lower to 3.32 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in functional profile in the 8 weeks before and after 4 weeks of treatment</b> </p> <p>Follow‐up: mean 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in functional profile in the 8 weeks before and after 4 weeks of treatment in the control group was <br/> <b>3.5</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in functional profile in the 8 weeks before and after 4 weeks of treatment in the intervention group was<br/> <b>1.10 lower</b> <br/> (1.81 to 0.39 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,8,9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sick days in 4 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sick days in 4 months in the control groups was<br/> <b>1.73</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sick days in 4 months in the intervention groups was<br/> <b>1.03 lower</b> <br/> (3.59 lower to 1.53 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Per‐protocol analysis while claiming an intention‐to‐treat analysis.<br/> <sup>2</sup>No description of reasons for drop‐out or treatment failure.<br/> <sup>3</sup>Overestimation of the effect of the placebo device (and underestimation of the effect of the Meniett device), because most treatment failures dropped out of the placebo group.<br/> <sup>4</sup>The decrease in days with vertigo is not significantly different in the treatment group compared to the placebo group in any of the follow‐up months.<br/> <sup>5</sup>Additional low‐sodium diet.<br/> <sup>6</sup>A high proportion of participants used diuretics (80% in the placebo group and 73% in the active treatment group).<br/> <sup>7</sup>Additional use of betahistine.<br/> <sup>8</sup>Unclear statistics.<br/> <sup>9</sup>Use of frequencies before insertion of the ventilation tube and after treatment, while claiming to rule out the effect of the ventilation tube. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008419-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008419-sec-0030"></div> <section id="CD008419-sec-0031"> <h3 class="title" id="CD008419-sec-0031">Description of the condition</h3> <p>Ménière's disease is an incapacitating disease in which recurrent attacks of vertigo are accompanied by hearing loss, tinnitus and/or aural fullness. The attacks of vertigo may follow each other with intervals of days, weeks or even months. Usually, these become less severe and disappear after two to eight years in 60% to 80% of sufferers with profound lasting hearing loss and tinnitus (<a href="./references#CD008419-bbs2-0044" title="PortmannG . The old and new in Meniere's disease ‐ over 60 years in retrospect and a look to the future. Otolaryngologic Clinics of North America1980;13(4):567‐75. ">Portmann 1980</a>; <a href="./references#CD008419-bbs2-0049" title="SilversteinH , SmouhaE , JonesR . Natural history vs. surgery for Meniere's disease. Otolaryngology ‐ Head and Neck Surgery1989;100(1):6‐16. ">Silverstein 1989</a>). However, there is great variability in the presentation and natural course of the disease. When no known cause of the disease is identified, the term Ménière's <i>disease</i> is applicable. When the symptoms are secondary to a known disease (e.g. meningitis), the term Ménière's <i>syndrome</i> is used. </p> <p>Few articles have been published on the epidemiology of Ménière's disease. Great variation exists in the published reports of the incidence and prevalence of Ménière's disease, ranging from 17 cases per 100,000 population in Japan (<a href="./references#CD008419-bbs2-0040" title="NakaeK , KomatuzakiK . Epidemiological study of Meniere's disease. Pract Otol (Kyoto)1984;69:1783‐8. ">Nakae 1984</a>) to 46 cases per 100,000 population in Sweden (<a href="./references#CD008419-bbs2-0050" title="StahleJ , StahleC , ArenbergIK . Incidence of Meniere's disease. Archives of Otolaryngology1978;104(2):99‐102. ">Stahle 1978</a>). There seems to be a slight female preponderance, with up to 1.3 times more women affected than men. The disease is more common in adults in their fourth and fifth decade of life (<a href="./references#CD008419-bbs2-0034" title="KotimakiJ , SorriM , AantaaE , NuutinenJ . Prevalence of Meniere disease in Finland. Laryngoscope1999;109(5):748‐53. ">Kotimaki 1999</a>; <a href="./references#CD008419-bbs2-0047" title="SajjadiH , PaparellaMM . Meniere's disease. Lancet2008;372(9636):406‐14. ">Sajjadi 2008</a>). The frequency of bilateral disease is unclear. Published reports vary greatly, from 2% to 78% (<a href="./references#CD008419-bbs2-0016" title="BalkanyTJ , SiresB , ArenbergIK . Bilateral aspects of Meniere's disease: an underestimated clinical entity. Otolaryngologic Clinics of North America1980;13(4):603‐9. ">Balkany 1980</a>). In a large population study by Kitahara in Japan, bilaterality of disease was noted in 9.1% of patients in their first year of experiencing symptoms. This increased steadily to 41.5% after 20 years of disease (<a href="./references#CD008419-bbs2-0033" title="KitaharaM . Bilateral aspects of Meniere's disease. Meniere's disease with bilateral fluctuant hearing loss. Acta Oto‐Laryngologica. Supplement1991;485:74‐7. ">Kitahara 1991</a>). </p> <p>In 1861, Prosper Ménière first recognised that this disorder originated from the inner ear (the membranous labyrinth), but wrongly attributed the cause to haemorrhage (<a href="./references#CD008419-bbs2-0037" title="MénièreP . Memoire sur les lesions de l'oreille interne donnant lieu à des symptômes de congestion cerebrale apoplectiforme. Gazette Medicale de Paris1861;16:597‐601. ">Meniere 1861</a>). In 1938, Hallpike and Yamakawa independently described a hydrops (i.e. accumulation of fluid) of the endolymphatic system in patients with Ménière's disease (<a href="./references#CD008419-bbs2-0028" title="HallpikeCS , CairnsH . Observations on the pathology of Menière's syndrome. Proceedings of the Royal Society of Medicine1938;31:1317‐31. ">Hallpike 1938</a>; <a href="./references#CD008419-bbs2-0053" title="YamakawaK . Uber die pathologische Veranderung bei einem Menière‐Kranken. Proceedings of the 42nd Annual Meeting of the the Oto‐Rhino‐Laryngological Society of Japan1938;44:2310‐2. ">Yamakawa 1938</a>). In 1965, Kimura introduced an experimental model in which an endolymphatic hydrops was produced in guinea pigs after surgical obliteration of the endolymphatic sac and duct (<a href="./references#CD008419-bbs2-0032" title="KimuraRS . Experimental blockage of the endolymphatic duct and sac and its effect on the inner ear of the guinea pig. A study on endolymphatic hydrops. Annals of Otology, Rhinology, and Laryngology1967;76(3):664‐87. ">Kimura 1967</a>). Endolymphatic hydrops caused by an abnormality in the absorption of endolymph at the endolymphatic sac remains the most promising theory to explain the symptoms of Ménière's disease. Other explanations for the cause of an endolymphatic hydrops, such as a hypoplasia of the vestibular aqueduct (<a href="./references#CD008419-bbs2-0022" title="EgamiT , SandoI , BlackFO . Hypoplasia of the vestibular aqueduct and endolymphatic sac in endolymphatic hydrops. Otolaryngology1978;86(2):327‐39. [PUBMED: 113739] ">Egami 1978</a>; <a href="./references#CD008419-bbs2-0054" title="YamamotoE , MizukamiC , OhmuraM . Investigation of the external aperture of the vestibular aqueduct in Meniere's disease by three‐dimensional image analysis. Acta Oto‐Laryngologica1992;112(1):31‐5. [PUBMED: 1575034] ">Yamamoto 1992</a>), a genetic predisposition (<a href="./references#CD008419-bbs2-0039" title="MorrisonAW . Anticipation in Meniere's disease. Journal of Laryngology and Otology1995;109(6):499‐502. ">Morrison 1995</a>), or a viral aetiology (<a href="./references#CD008419-bbs2-0052" title="VrabecJT . Herpes simplex virus and Meniere's disease. Laryngoscope2003;113(9):1431‐8. ">Vrabec 2003</a>), have been suggested. </p> <p>Currently no 'gold standard' diagnostic test for Ménière's disease exists. Diagnostic criteria vary among practitioners, who mostly diagnose Ménière's disease based upon the patient's history, neurotologic evaluation and clinical response to medical treatment. In 1972, the American Academy of Otolaryngology ‐ Head and Neck Surgery (AAO‐HNS) produced diagnostic guidelines (<a href="./references#CD008419-bbs2-0015" title="AlfordBR . Menière's disease: criteria for diagnosis and evaluation of therapy for reporting. Report of subcommittee on equilibrium and its measurement. Transactions of the American Academy of Ophthalmology and Otolaryngology1972;76:1462‐4. ">Alford 1972</a>), which were revised in 1985 (<a href="./references#CD008419-bbs2-0043" title="PearsonBW , BrackmannDE . Committee on Hearing and Equilibrium guidelines for reporting treatment results in Meniere's disease. Otolaryngology ‐ Head and Neck Surgery1985;93(5):579‐81. ">Pearson 1985</a>) and 1995 (<a href="./references#CD008419-bbs2-0038" title="MonsellEM . New and revised reporting guidelines from the Committee on Hearing and Equilibrium. American Academy of Otolaryngology ‐ Head and Neck Surgery Foundation, Inc. Otolaryngology ‐ Head and Neck Surgery1995;113(3):176‐8. ">Monsell 1995</a>). According to these guidelines Ménière's disease is 'definite' when the last two spontaneous episodes of vertigo occur for at least 20 minutes, hearing loss of at least 20 decibels (dB) is objectified and tinnitus or aural fullness in the affected ear is experienced. Further investigation has to be performed to exclude any other disorder (<a href="./references#CD008419-bbs2-0038" title="MonsellEM . New and revised reporting guidelines from the Committee on Hearing and Equilibrium. American Academy of Otolaryngology ‐ Head and Neck Surgery Foundation, Inc. Otolaryngology ‐ Head and Neck Surgery1995;113(3):176‐8. ">Monsell 1995</a>). When patients match the AAO‐HNS criteria, but symptoms are secondary to a known cause, they are classified as having Ménière's syndrome. </p> <p>A number of different treatment modalities have been identified for this disease, ranging from dietary measures (e.g. a low‐salt diet) and medication (e.g. betahistine (Serc®), diuretics) to extensive surgery (e.g. endolymphatic sac surgery). Although a large number of studies have been conducted on therapy for Ménière's disease (see the Cochrane reviews of diuretics, betahistine and surgery: <a href="./references#CD008419-bbs2-0017" title="BurgessA , KunduS . Diuretics for Ménière's disease or syndrome. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD003599.pub2] ">Burgess 2006</a>; <a href="./references#CD008419-bbs2-0031" title="JamesAL , BurtonMJ . Betahistine for Meniere's disease or syndrome. Cochrane Database of Systematic Reviews2001, Issue 1. [DOI: 10.1002/14651858.CD001873] ">James 2001</a>; <a href="./references#CD008419-bbs2-0045" title="PullensB , VerschuurHP , vanBenthemPP . Surgery for Ménière's disease. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD005395.pub3] ">Pullens 2013</a>), an effective evidence‐based therapy has never been established. Ménière's disease has a fluctuating natural course with remissions and exacerbations. Spontaneous remission is not uncommon, which makes evaluation of treatment difficult. The AAO‐HNS therefore advises a follow‐up period of at least two years to evaluate therapy (<a href="./references#CD008419-bbs2-0018" title="CoelhoDH , LalwaniAK . Medical management of Meniere's disease. Laryngoscope2008;118(6):1099‐108. ">Coelho 2008</a>; <a href="./references#CD008419-bbs2-0021" title="DurlandWFJr , PyleGM , ConnorNP . Endolymphatic sac decompression as a treatment for Meniere's disease. Laryngoscope2005;115(8):1454‐7. ">Durland 2005</a>; <a href="./references#CD008419-bbs2-0026" title="GhossainiSN , WazenJJ . An update on the surgical treatment of Meniere's diseases. Journal of the American Academy of Audiology2006;17(1):38‐44. ">Ghossaini 2006</a>; <a href="./references#CD008419-bbs2-0042" title="OdkvistL . Pressure treatment versus gentamicin for Meniere's disease. Acta Oto‐Laryngologica2001;121(2):266‐8. ">Odkvist 2001</a>). </p> </section> <section id="CD008419-sec-0032"> <h3 class="title" id="CD008419-sec-0032">Description of the intervention</h3> <p>Positive pressure therapy is a relatively new, minimally invasive method of treatment for Ménière's disease. In initial attempts to influence inner ear fluid pressure, a pressure chamber was used with the possibility of altering air pressure within a range of ± 110 cm H<sub>2</sub>O (<a href="./references#CD008419-bbs2-0030" title="IngelstedtS , IvarssonA , TjernstromO . Immediate relief of symptoms during acute attacks of Meniere's disease, using a pressure chamber. Acta Oto‐Laryngologica1976;82(5‐6):368‐78. ">Ingelstedt 1976</a>). <a href="./references#CD008419-bbs2-0051" title="TjernstromO . Effects of middle ear pressure on the inner ear. Acta Oto‐Laryngologica1977;83(1‐2):11‐5. ">Tjernstrom 1977</a> described the effects of positive pressure in the middle ear on the inner ear fluids and subsequently treated patients with Ménière's disease with overpressure in the middle ear. Densert et al presented a new method of local application of pressure in 1982, which was later developed in the Meniett® device (<a href="./references#CD008419-bbs2-0019" title="DensertB , DensertO . Overpressure in treatment of Meniere's disease. Laryngoscope1982;92(11):1285‐92. [PUBMED: 6983015] ">Densert 1982</a>; <a href="./references#CD008419-bbs2-0042" title="OdkvistL . Pressure treatment versus gentamicin for Meniere's disease. Acta Oto‐Laryngologica2001;121(2):266‐8. ">Odkvist 2001</a>). </p> <p>The Meniett is a small, low‐pressure generator that delivers a computer‐controlled, complex algorithm of pulses at a frequency of 6 kHz for 0.6 seconds. After rising to a pressure level of 1.2 kPa, the pressure then oscillates between 0.4 and 1.2 kPa. In order to translate the pressure pulses to the middle ear (namely to the round window membrane), a ventilation tube has to be placed in the tympanic membrane, which requires a small surgical procedure. The device is portable and self administered, requiring a five‐minute session three times each day, or more when vertigo exists. The Meniett device was approved by the US Food and Drug Administration for the treatment of Ménière's disease in 2002. </p> </section> <section id="CD008419-sec-0033"> <h3 class="title" id="CD008419-sec-0033">How the intervention might work</h3> <p>A number of animal studies have been undertaken to study the effect of middle ear pressure changes on inner ear pressure. Feijen et al monitored inner ear pressure in guinea pigs while applying pressure changes to the middle ear by using the Meniett 20® device in the outer ear canal (<a href="./references#CD008419-bbs2-0023" title="FeijenRA , SegenhoutJM , WitHP , AlbersFW . Monitoring inner ear pressure changes in normal guinea pigs induced by the Meniett20. Acta Oto‐Laryngologica2000;120(7):804‐9. ">Feijen 2000</a>). They found that middle ear pressure changes induced by the Meniett 20® were instantly transferred to the inner ear fluid. A single pressure pulse by the Meniett resulted in an increase of inner ear pressure and an 'undershoot' of pressure at the end of the pressure pulse, in which the inner ear pressure is lower than before application of the pressure pulse. In a number of seconds, inner ear pressure recovered to normal. In a follow‐up study, different types of pressure pulses were used (<a href="./references#CD008419-bbs2-0024" title="FeijenRA , SegenhoutJM , AlbersFW , WitHP . Change of guinea pig inner ear pressure by square wave middle ear cavity pressure variation. Acta Oto‐Laryngologica2002;122(2):138‐45. [PUBMED: 11936904] ">Feijen 2002</a>). When applying a constant increase in middle ear pressure, inner ear pressure increases accordingly, but immediately decreases to a new steady‐state pressure (which is a little higher than the starting pressure) in a couple of seconds. When positive middle ear pressure ceases, inner ear pressure drops to negative and increases to normal in a couple of seconds. </p> <p>In another animal study, Sakikawa et al demonstrated that appliance of pressure (49.2 cm H<sub>2</sub>O) in the external ear canal inhibited the formation of endolymphatic hydrops in guinea pigs after blockage of the endolymphatic duct (<a href="./references#CD008419-bbs2-0048" title="SakikawaY , KimuraRS . Middle ear overpressure treatment of endolymphatic hydrops in guinea pigs. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1997;59(2):84‐90. ">Sakikawa 1997</a>). </p> <p>Densert et al measured cochlear potential through electrocochleography while applying middle ear pressure pulses in a double‐blind, placebo‐controlled trial. In the placebo group no changes in electrocochlear parameters were found. In the active group, electrocochlear parameters indicated an improvement in inner ear electrophysiology (<a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a>). </p> <p>Several hypotheses have been proposed to account for the effects of pressure variations in the middle ear on the inner ear fluids. It has been suggested that pressure increase in the middle ear causes a decongestion of the labyrinthine vascular bed, improving endolymphatic drainage. Others propose that a pressure increase in the perilymphatic compartment influences the endolymphatic pressure. It is theorised that the energy of the pressure pulses displaces the perilymphatic fluid, which stimulates the flow of endolymphatic fluid either through the endolymphatic duct, or to the stria vascularis or surrounding tissues (<a href="./references#CD008419-bbs2-0023" title="FeijenRA , SegenhoutJM , WitHP , AlbersFW . Monitoring inner ear pressure changes in normal guinea pigs induced by the Meniett20. Acta Oto‐Laryngologica2000;120(7):804‐9. ">Feijen 2000</a>; <a href="./references#CD008419-bbs2-0048" title="SakikawaY , KimuraRS . Middle ear overpressure treatment of endolymphatic hydrops in guinea pigs. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1997;59(2):84‐90. ">Sakikawa 1997</a>). </p> </section> <section id="CD008419-sec-0034"> <h3 class="title" id="CD008419-sec-0034">Why it is important to do this review</h3> <p>There is no real cure for Ménière's disease, although a number of different treatments exist. To our knowledge, no systematic review of positive pressure therapy has yet been conducted, while a number of randomised controlled trials have been carried out. A possible beneficial effect is suggested, but the extent of the effect is uncertain. A Cochrane review assessing the effects of positive pressure therapy in the treatment of Ménière's disease or syndrome is therefore warranted. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008419-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008419-sec-0035"></div> <p>To assess the effects of positive pressure therapy (e.g. the Meniett device) on the symptoms of Ménière's disease or syndrome. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008419-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008419-sec-0036"></div> <section id="CD008419-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008419-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials.</p> </section> <section id="CD008419-sec-0039"> <h4 class="title">Types of participants</h4> <p>Patients suffering from Ménière's disease not otherwise controlled by conservative therapy and without a history of surgical intervention. We graded as 'I' studies that had used the AAO‐HNS criteria for Ménière's disease or syndrome, and which only included patients with 'definite' or 'certain' Ménière's disease. We graded as 'II' studies that included participants in which clear but less rigorous criteria were used. We graded as 'III' studies in which less clear criteria were used (<a href="./references#CD008419-bbs2-0013" title="Committee on Hearing and Equilibrium. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology ‐ Head and Neck Foundation, Inc. Otolaryngology ‐ Head and Neck Surgery1995;113(3):181‐5. ">AAO‐HNS 1995</a>; <a href="./references#CD008419-bbs2-0031" title="JamesAL , BurtonMJ . Betahistine for Meniere's disease or syndrome. Cochrane Database of Systematic Reviews2001, Issue 1. [DOI: 10.1002/14651858.CD001873] ">James 2001</a>).  </p> </section> <section id="CD008419-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Positive pressure therapy using the Meniett device or any other device or pressure chamber used to create overpressure in the middle or inner ear. This device should be compared with placebo, for example a sham device (a Meniett device which does not generate pressure pulses or an identical‐looking device without pressure generation). </p> </section> <section id="CD008419-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD008419-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008419-list-0001"> <li> <p>Control of vertigo or decrease in vertigo attacks</p> </li> </ul> </p> <p>The AAO‐HNS Committee on Hearing and Equilibrium proposed the "control of vertigo" as a main objective outcome measure when assessing therapy in Ménière's disease. The number of vertigo attacks in the interval between 18 and 24 months after treatment (y) is divided by the number of vertigo spells for the period of six months prior to the treatment (x) and multiplied by 100. The resulting number indicates the extent of "control of vertigo". The AAO‐HNS further divides the control of vertigo (CoV) into classes, where Class A (CoV = 0) is complete control and class B (CoV 1 to 40) is substantial control. A minimum duration of follow‐up of at least two years is advised by the AAO‐HNS (<a href="./references#CD008419-bbs2-0013" title="Committee on Hearing and Equilibrium. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology ‐ Head and Neck Foundation, Inc. Otolaryngology ‐ Head and Neck Surgery1995;113(3):181‐5. ">AAO‐HNS 1995</a>). </p> <p>We also considered studies with a shorter period of follow‐up.</p> </section> <section id="CD008419-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008419-list-0002"> <li> <p>Loss or gain of hearing</p> </li> <li> <p>Severity of tinnitus</p> </li> <li> <p>Perception of aural fullness</p> </li> <li> <p>Functional level</p> </li> <li> <p>Complications and adverse events</p> </li> <li> <p>Sick days</p> </li> </ul> </p> <p>In the protocol we described 'quality of life' as a secondary outcome measure. In this review we have changed this to 'functional level', as this parameter is used in different studies and it is a derivate of everyday function and therefore quality of life. For the sake of clarity, the term functional level is used. </p> <p>Additionally, we added 'sick days' as a secondary outcome because two studies included this measurement and because it is a complementary measurement of impairment due to Ménière's disease and can be related to quality of life. </p> </section> </section> </section> <section id="CD008419-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted systematic searches for randomised controlled trials. There were no language, publication year or publication status restrictions. The date of the latest search was 6 June 2014 (see <a href="#CD008419-fig-0001">Figure 1</a> for a flow chart of the search process). </p> <div class="figure" id="CD008419-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Process for sifting search results and selecting studies for inclusion." data-id="CD008419-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Process for sifting search results and selecting studies for inclusion.</p> </div> </div> </div> <section id="CD008419-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases from their inception for published, unpublished and ongoing trials: the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 5); PubMed; EMBASE; CINAHL; AMED; LILACS; KoreaMed; IndMed; PakMediNet; CAB Abstracts; Web of Science; ISRCTN; ClinicalTrials.gov; ICTRP; Google Scholar and Google. In searches prior to 2013, we also searched BIOSIS Previews 1926 to 2012. </p> <p>We modelled subject strategies for databases on the search strategy designed for CENTRAL. Where appropriate, we combined subject strategies with adaptations of the highly sensitive search strategy designed by The Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1.0, Box 6.4.b. (<a href="./references#CD008419-bbs2-0029" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Handbook 2011</a>)). Search strategies for major databases including CENTRAL are provided in <a href="./appendices#CD008419-sec-0113">Appendix 1</a>. </p> </section> <section id="CD008419-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We scanned the reference lists of identified publications for additional trials and contacted authors where necessary. In addition, we scanned the reference lists of a previous review on the subject and the review authors' own files for relevant studies. We handsearched conference proceedings for details of further trials and searched for unpublished trials by contacting the manufacturer (Medtronics). </p> </section> </section> <section id="CD008419-sec-0047"> <h3 class="title" id="CD008419-sec-0047">Data collection and analysis</h3> <section id="CD008419-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two authors scanned the initial search results to identify trials that loosely met the inclusion criteria. The two authors then independently used titles, keywords and (where available) abstracts of the identified citations to exclude trials that clearly did not meet the inclusion criteria for the review. If one of the authors concluded that the trial might possibly meet the criteria, we obtained the full paper for further study. Both authors assessed the hard copies of the articles passing this initial screening to determine whether they met the inclusion criteria. We compared the results of the two independent selections. We resolved any disagreements by discussion. </p> </section> <section id="CD008419-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>The two authors independently extracted data from the studies using a standardised data extraction form. We additionally extracted the following data: AAO‐HNS grade of diagnosis, type of device used, treatment protocol used (number of applications per day, total number of applications, duration of use of the device) and follow‐up. There was no blinding of journal or author names and affiliations. Where necessary and where sufficient data from the study were not provided, we wrote to the authors of the study requesting further information. </p> </section> <section id="CD008419-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the quality of the selected studies using The Cochrane Collaboration's tool for assessing risk of bias. This tool addresses the following domains: </p> <p> <ol id="CD008419-list-0003"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants, personnel and outcome assessors;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other sources of bias.</p> </li> </ol> </p> <p>Two authors judged each of these domains according to the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (see below): low, high and unclear (or uncertain) risk of bias. These results are presented in <a href="#CD008419-fig-0002">Figure 2</a> and <a href="#CD008419-fig-0003">Figure 3</a> and incorporated into the 'Risk of bias' tables using RevMan 5 (<a href="./references#CD008419-bbs2-0046" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). See <a href="./references#CD008419-sec-0125" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD008419-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD008419-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008419-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008419-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>We also judged two extra domains: the certainty of the diagnosis of Ménière's disease (see also <a href="#CD008419-sec-0039">Types of participants</a>) and the quality of outcome assessment (see <a href="#CD008419-sec-0041">Types of outcome measures</a>). This is a modification of the 'Risk of bias' tool following an earlier Ménière's disease review by James and colleagues (<a href="./references#CD008419-bbs2-0031" title="JamesAL , BurtonMJ . Betahistine for Meniere's disease or syndrome. Cochrane Database of Systematic Reviews2001, Issue 1. [DOI: 10.1002/14651858.CD001873] ">James 2001</a>). </p> <p>The Cochrane Collaboration's tool for assessing risk of bias is described in <a href="#CD008419-tbl-0002">Table 1</a> (<a href="./references#CD008419-bbs2-0029" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Handbook 2011</a>). </p> <div class="table" id="CD008419-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane 'Risk of bias' tool</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Domain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Review authors' judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was the allocation sequence adequately generated?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was allocation adequately concealed?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinding of participants, personnel and outcome assessors</b> <br/> <i>Assessments should be made for each main outcome (or class of outcomes)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was knowledge of the allocated intervention adequately prevented during the study?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incomplete outcome data</b> <br/> <i>Assessments should be made for each main outcome (or class of outcomes)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomised participants), reasons for attrition/exclusions where reported, and any re‐inclusions in analyses performed by the review authors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Were incomplete outcome data adequately addressed?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selective outcome reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>State how the possibility of selective outcome reporting was examined by the review authors and what was found </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Are reports of the study free of suggestion of selective outcome reporting?</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD008419-sec-0051"> <h4 class="title">Dealing with missing data</h4> <p>When critical data were not reported in the included studies, we contacted the principal investigator and request the data. Dr Gurkov responded with additional data (<a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a>). Additional data from Dr Gates are awaited (<a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a>). The other authors were unreachable or did not respond to our request. </p> </section> <section id="CD008419-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>Where possible, we pooled study results using fixed‐effect meta‐analysis to calculate mean differences (MD). We tested statistical heterogeneity with both the I<sup>2</sup> statistic and the Chi<sup>2</sup> test. An I<sup>2</sup> value greater than 50% is considered to indicate substantial heterogeneity (<a href="./references#CD008419-bbs2-0029" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Handbook 2011</a>). If the I<sup>2</sup> value was 50% or less, we used a fixed‐effect meta‐analysis (<a href="./references#CD008419-bbs2-0035" title="MantelN , HaensxelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22:719‐48. ">Mantel 1959</a>). If the I<sup>2</sup> value was greater than 50%, we explored the individual trial characteristics to identify potential sources of heterogeneity. We then performed meta‐analysis using both fixed‐effect and random‐effects modelling (<a href="./references#CD008419-bbs2-0020" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">DerSimonian 1986</a>), to assess sensitivity to the choice of modelling approach. </p> </section> <section id="CD008419-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not test for funnel plot asymmetry as there were fewer than 10 studies included in the meta‐analysis (<a href="./references#CD008419-bbs2-0029" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Handbook 2011</a>). </p> </section> <section id="CD008419-sec-0054"> <h4 class="title">Data synthesis</h4> <p>We planned that data analysis would be by intention‐to‐treat. In this review, for the primary outcome of control of vertigo or decrease in vertigo attacks the data were not compatible and of sufficient quality, therefore it was not possible to combine data in meta‐analysis. For the secondary outcomes loss or gain of hearing and sick days, we pooled the results to present an overall estimate of the treatment effect. We used fixed‐effect or random‐effects meta‐analysis depending on the degree of heterogeneity (see above). </p> <p>Additionally we compared the duration of usage of the device and the duration of follow‐up between all studies, but this was not used in any analysis. </p> </section> <section id="CD008419-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>A subgroup analysis comparing the type of overpressure device used (Meniett device, pressure chamber) was not possible due to heterogeneity between studies. We extracted subgroup data for the secondary outcome measures and tested for heterogeneity as described above. </p> </section> <section id="CD008419-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p>As described above, due to clinical heterogeneity we only performed a meta‐analysis for the secondary outcome measures. We had planned to use study quality in a sensitivity analysis had this been appropriate. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008419-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008419-sec-0057"></div> <section id="CD008419-sec-0058"> <h3 class="title">Description of studies</h3> <section id="CD008419-sec-0059"> <h4 class="title">Results of the search</h4> <p>Our electronic database searches in June 2014 retrieved 211 initial results. After removal of duplicates and obviously irrelevant studies this number dropped to 64 reports. After the second selection, we removed 52 reports, either because they did not fit the inclusion criteria or because they were not RCTs. We retrieved 12 articles in full text. Of these, we excluded seven because they did not meet the inclusion criteria, did not compare positive pressure therapy with placebo or were not RCTs after further analysis (see <a href="#CD008419-sec-0076">Excluded studies</a> and <a href="./references#CD008419-sec-0126" title="">Characteristics of excluded studies</a> for further details). Two articles were reviews and we scanned them for additional references, but found none. There are no ongoing studies or studies awaiting assessment. </p> <p>We selected five studies for inclusion in the review (<a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a>; <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a>; <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a>; <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a>; <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a>). This selection was made by two independent review authors (SvS and PPvB). A summary of the results of the search is presented in a flow diagram (<a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#FIG-01" target="_blank">Figure 1</a>). </p> </section> <section id="CD008419-sec-0060"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD008419-sec-0125" title="">Characteristics of included studies</a>. </p> <section id="CD008419-sec-0061"> <h5 class="title">Design</h5> <p>All five included studies were prospective, randomised and placebo‐controlled.</p> </section> <section id="CD008419-sec-0062"> <h5 class="title">Sample sizes</h5> <p>Study sample sizes ranged from 39 to 74. The total number of participants in the included studies was 265. </p> </section> <section id="CD008419-sec-0063"> <h5 class="title">Setting</h5> <p>All studies were multicentre and took place at centres in Sweden, Denmark, Norway, Germany and the USA. </p> </section> <section id="CD008419-sec-0064"> <h5 class="title">Participants</h5> <p>All five studies included patients with Ménière's disease.</p> <p>The <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> study used the clinical criteria of the AAO‐HNS 1995 Committee on Hearing and Equilibrium (Grade I). The inclusion criteria are: active clinical symptoms of Ménière's disease, cochlear hearing loss, aural pressure and recurrent spells of vertigo or dizziness six weeks prior to the intervention. The diagnosis of Ménière's disease was established at least one year but no longer than six years earlier: hearing loss was within the range of 20 dB to 65 dB pure‐tone average, seven or more points on the Gibson's 10‐point Ménière's scale (<a href="./references#CD008419-bbs2-0027" title="GibsonWPR . The 10‐point score for the clinical diagnosis of Ménière's disease. Proceedings of the Third International Symposium and Workshops on the Surgery of the Inner Ear. Amsterdam: Kugler Publications, 1991:109. ">Gibson 1991</a>; <a href="./appendices#CD008419-sec-0115">Appendix 3</a>), electrocochleographic summated potential/action potential (SP/AP) ratio above 33%, age was 20 to 65 years and there was a patent ventilation tube in the tympanic membrane. All measurements, including electrocochleographic recordings, were performed before exposure to the active or placebo treatment, one week later in most patients. The patients who fulfilled the inclusion criteria were included in the study. Of these 39 participants, 21 were randomly assigned to active treatment and 18 to placebo. Demographic characteristics were not reported. </p> <p>In the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> study, the AAO‐HNS criteria were not explicitly mentioned (Grade II). A total of 116 participants were contacted of whom 67 were eligible for inclusion and these were randomised for the study. The original sample size was 52, but an interim power analysis was performed halfway into the study, which suggested an increase in sample size by 10 patients. The active treatment group included 30 patients, with a mean age of 49.7 (range 34 to 67) and 67% were female. The placebo group contained 32 patients, with a mean age of 48.8 (range 36 to 71) and 69% were female. Both groups had a median duration of symptoms of 4.5 years (range two to seven years). Inclusion criteria were a clinical diagnosis of definite Ménière's disease, at least two vertigo attacks per month in the two months prior to the study and despite a low‐sodium diet with or without diuretics for at least three months. Additional inclusion criteria were documented low‐frequency sensorineural hearing loss and a history of fluctuating hearing, a functional level of 2 to 4, normal auditory brainstem responses and abnormal electrocochleography in the affected ear. Patients with 30% or greater canal weakness, measured with standard bithermal caloric tests, were excluded from randomisation. </p> <p>In the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study, the AAO‐HNS criteria were used for the diagnosis of Ménière's disease (Grade I). In total 154 patients met the inclusion criteria, but 74 patients were included. The power to detect a treatment effect was calculated as 80% (definite vertigo days, standard deviation (SD) = 5, difference in means = 3, n = 70). Demographic characteristics for included patients were provided. In the active group (n = 38) the mean age was 57 years (range 24 to 85), 19 patients were male and the mean duration of disease was 43 months. The placebo group patients (n = 36) had a mean age of 52 (range 19 to 74), 19 were male and the mean duration of disease was 57 months. To be included patients had to have had two or more episodes of vertigo lasting at least 20 minutes per month in the last two months and treatment with betahistine for three months. </p> <p>In the <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study, the AAO‐HNS criteria are not described and patient characteristics are not given (Grade III). Fifty‐six patients completed the study (n = 31 treatment, n = 25 control). Mean age, sex and duration of the disease are not reported; nor is the number of randomised patients or the power needed to detect a treatment effect. Inclusion criteria for this study were clinical and electrophysiological criteria for definite Ménière's disease, hearing impairment of 20 dB to 65 dB pure‐tone average and "active vestibular symptoms close to the test". </p> <p><a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> used the AAO‐HNS criteria for the diagnosis of Ménière's disease (Grade I). A total of 63 patients met the first entry criteria, but 23 were later excluded. A total of 40 patients were included after the second entry and were used for analysis. The active treatment group contained 20 patients, aged between 26 and 69 years and with a duration of disease of between one and 36 months. The placebo group contained 20 patients, aged 20 to 61 and with a duration of disease of one to 20 months. According to the authors, both groups were identical in age, sex and duration of disease (although no exact data or analyses are available). Included patients required a diagnosis of Ménière's disease based on the AAO‐HNS criteria, with a stage of 2 or 3, and a functional level of at least 3, hearing loss in the range of 20 dB to 65 dB pure‐tone average in the frequencies 500 Hz, 1 kHz, 2 kHz and 3 kHz. Additionally, all patients needed a score of at least seven on the Gibson scale (<a href="./references#CD008419-bbs2-0027" title="GibsonWPR . The 10‐point score for the clinical diagnosis of Ménière's disease. Proceedings of the Third International Symposium and Workshops on the Surgery of the Inner Ear. Amsterdam: Kugler Publications, 1991:109. ">Gibson 1991</a>; <a href="./appendices#CD008419-sec-0115">Appendix 3</a>), to be between 20 and 65 years of age and to have had at least eight vertigo attacks for at least 20 minutes during the previous year. For the second entry, after a period of two months monitoring, patients were only included with a minimum of two vertigo attacks lasting at least 20 minutes in the two months prior to and in the two months after ventilation tube placement. </p> </section> <section id="CD008419-sec-0065"> <h5 class="title">Intervention</h5> <p>In the <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> study, a ventilation tube was inserted in all patients. A portable air pressure generator was used to deliver pressure changes within the range of 0 to 3 kPa. The generator was designed so that no negative pressure could be delivered. It is not specified which type of pressure generator was used. Measurements of the generator noise levels showed levels of 0 dB to 10 dB normalised hearing level for the active apparatus and 0 dB for the placebo device. The total amplitude of the pressure pulses was a maximum of 1.7 kPa, and the amplitude of the static pressure component was approximately two‐thirds of the total amplitude. The frequency of modulation was 6 Hz and the duration of the pulse was 0.6 seconds with an interval of 4.4 seconds. The placebo device was an identical‐looking pressure generator, displaying the same light patterns without pressure pulses. Exposure to pressure pulses was conducted for three minutes and repeated again for three more minutes after a one‐minute period of refraction in between. Total time of exposure was at least six minutes. If patients reported an increase in aural fullness after the first three minutes of exposure, the pressure level was decreased to 1.0 kPa after a period of rest of approximately 20 minutes. Follow‐up was immediate. </p> <p>In the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> study, a ventilation tube was placed in all patients followed by a two‐week observation period (to rule out short‐term effects of tube placement on symptoms). After two weeks, in the active treatment group the Meniett device was used to deliver 0.6 second pressure pulses at 6 Hz within the range of 0 to 20 cm H<sub>2</sub>O to the ear. The five‐minute treatment sequence had three cycles, each with one minute of pressure pulses and 40 seconds of pause. The placebo device was identical in appearance and produced a similar clicking sound and light display to the actual device during operation. The Meniett device and the placebo device were self administered three times daily. Follow‐up assessments were scheduled monthly for a total period of four months. At the second and fourth visit, audiometry and electrocochleography were repeated. Additionally, participants were instructed to maintain a 1500 mg/day sodium diet. Participants were furthermore allowed to use their pre‐study medication as needed. </p> <p><a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> used a ventilation tube in all patients, with the Meniett device in the active group and a placebo device with identical acoustic properties to the Meniett device, which only produced a slight pressure increase of 2 cm H<sub>2</sub>O. The Meniett device delivered 0.6 second pressure pulses at 6 Hz within a range of 0 to 20 cm H<sub>2</sub>O to the ear canal. The five‐minute treatment sequence had three cycles, each with one minute of pressure pulses and 40 seconds of no pressure pulses. The device was used three times daily (morning, afternoon and evening). All patients were first observed for four weeks before insertion of the ventilation tube. After insertion of the ventilation tube, all patients were observed again for four weeks. This was followed by a study period of 16 weeks, in which the active treatment group received low‐pressure therapy and visited the study centre at four‐week intervals. Patients were advised to continue their (pre‐existing) daily dosis of betahistine of 48 to 72 mg/day. The study had a four‐month follow‐up period. </p> <p>In the <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study, a ventilation tube was inserted in the tympanic membrane in all patients, followed by a two‐week observation period. Patients who fulfilled the inclusion criteria after this two‐week period were included in the study. The active device (Meniett device) generated repeated pressure pulses in the middle ear, with pressure applications of the amplitude of 120 mm H<sub>2</sub>O and consisted of complex pressure pulses and a 6 Hz sinusoidal modulation. The duration of each pulse was 0.6 seconds. The placebo device looked similar, but gave no stimulation to the ear. Duration and frequency of application was not described. Follow‐up was after two weeks. </p> <p>In the <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> study, a ventilation tube with a diameter of 1.25 mm was inserted through the tympanic membrane in all patients, followed by a two‐month observation period. In the active treatment group, the Meniett device was used. Neither the frequency and duration of the pulses, nor the daily frequency were described in either group. The treatment period was two months, with follow‐up at two, four and eight weeks. The placebo device was identical in appearance and produced a similar clicking sound and light display to the actual device during operation. The placebo device did not give any pressure pulse, except a slight pressure increase to 2 cm H<sub>2</sub>O for five seconds to maintain the leakage test. </p> </section> <section id="CD008419-sec-0066"> <h5 class="title">Outcome measures: primary outcome measures</h5> <section id="CD008419-sec-0067"> <h6 class="title">Control of vertigo</h6> <p>In the <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> study, vertigo was measured with a visual analogue scale (VAS) as a secondary outcome measure. The VAS was not specified. </p> <p>In the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> study, participants scored their vertigo complaints daily on a four‐point VAS on which 0 is a vertigo‐free day and 4 is the worst vertigo attack ever experienced. A definitive vertigo day was any day with a vertigo score of 2, 3 or 4. Vertigo complaints were summarised in two ways: (1) vertigo severity, the monthly total of counted vertigo scores and (2) vertigo frequency, the proportion of counted vertigo days per time period. The proportion of sick days, days with an activity level of 3 or 4, was calculated over a period of four months. </p> <p>In the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study, primary and secondary outcome measures are not specified. Vertigo was assessed using a five‐point Likert scale. A vertigo‐free day was scored as 0, days with mild attacks were scored as 1, moderately severe attacks lasting more than 20 minutes were scored as 2, severe attacks lasting an hour or more or accompanied by nausea or vomiting were scored as 3. A level 4 attack was the worst attack ever experienced to date. A definite vertigo day was any day with a vertigo score of 2 or more. For statistical analysis a vertigo score was used, which was a cumulative score over a period of four weeks. Additionally, sick days were defined as days with an activity score of 3 or 4. </p> <p>In the <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> study, the frequency of vertigo attacks in the two months before the treatment period and in the last four weeks of the treatment period of four months was calculated. Additionally, the perception of vertigo was evaluated on a VAS in a daily diary. The VAS was not specified. </p> <p>In the <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study, primary and secondary outcome measures were not specified. Self reports (VAS) were used to assess vertigo and dizziness. This VAS was not specified. </p> </section> </section> <section id="CD008419-sec-0068"> <h5 class="title">Outcome measures: secondary outcome measures</h5> <section id="CD008419-sec-0069"> <h6 class="title">Loss or gain of hearing</h6> <p>In the <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> study, hearing loss was not measured. </p> <p><a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> measured the average low‐frequency hearing thresholds (0.25 kHz, 0.5 kHz, 1 kHz) before the start of therapy and compared those with average thresholds at two and four months follow‐up. </p> <p>In the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study, pure‐tone audiometry and air caloric irrigation testing were performed at every visit. The mean hearing threshold, assessed by pure‐tone average at 0.25 kHz to 1 kHz was calculated. </p> <p>In the <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study, pure‐tone audiometry was used to measure hearing loss at 500 kHz, 1000 kHz and 2000 Hz. </p> <p><a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> stated that audiological evaluation occurred before and after the treatment period and the perception of hearing was analysed using a VAS. </p> </section> <section id="CD008419-sec-0070"> <h6 class="title">Severity of tinnitus</h6> <p><a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> and <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> used a VAS to measure tinnitus. </p> <p>In the studies of <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> and <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> tinnitus was not an outcome parameter. </p> <p><a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> evaluated change in tinnitus on a VAS scale. </p> </section> <section id="CD008419-sec-0071"> <h6 class="title">Perception of aural fullness</h6> <p><a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a>, <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> and <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> evaluated change in the perception of aural fullness on a VAS. </p> <p>In the studies of <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> and <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a>, aural fullness was not an outcome parameter. </p> </section> <section id="CD008419-sec-0072"> <h6 class="title">Functional level</h6> <p>In the protocol we described 'quality of life' as a secondary outcome measure. In this review we have changed this to 'functional level', as this parameter is used in different studies and it is a derivate of everyday function and therefore quality of life. For the sake of clarity, the term functional level is used. Quality of life was not used as an outcome measure in any of the included studies. </p> <p>Activity level or functional level was not measured in the <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> study. </p> <p>In the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> study, activity level was scored using a 0 to 4 Likert scale: 0 indicated no reduction in activity; 1 and 2 indicated minor or moderate reductions in activity, respectively, without having to cancel a planned schedule; 3 indicated the need to stay at home, leave work or cancel a planned schedule; and 4 indicated being bedridden or largely incapacitated during the day. Use of the (symptom report) cards began before the initial clinical visit to record baseline symptom levels during the one‐month pre‐randomisation assessment period. </p> <p>In the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study, activity level was scored using a 0 to 4 Likert scale: 0 indicated no reduction in activity; 1 and 2 indicated minor or moderate reductions in activity, respectively, without having to cancel a planned schedule; 3 indicated the need to stay at home, leave work or cancel a planned schedule; and 4 indicated being bedridden or largely incapacitated during the day. In this study, sick days were also registered as an activity score of 3 or 4. </p> <p><a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> used a questionnaire to investigate the functional level in daily life and at work. This questionnaire is not further described. </p> <p><a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> used the functionality profile suggested by the AAO‐HNS (<a href="./references#CD008419-bbs2-0013" title="Committee on Hearing and Equilibrium. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology ‐ Head and Neck Foundation, Inc. Otolaryngology ‐ Head and Neck Surgery1995;113(3):181‐5. ">AAO‐HNS 1995</a>); this is a one‐ to six‐point scale. </p> </section> <section id="CD008419-sec-0073"> <h6 class="title">Adverse effects</h6> <p>Adverse effects were not noted by <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a>, <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> or <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a>. </p> <p>In the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study, no adverse effects were noted. However, three participants were excluded, one because of treatment failure and two because of non‐compliance. Another participant left without reason. There is no explanation of treatment failure or non‐compliance. No adverse effects were reported, although one participant suffered from self limiting otitis media related to the ventilation tube. </p> <p>In the <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> study, no adverse effects were noted but 23 participants were excluded from analysis because of non‐compliance with the treatment or study protocol. It is unclear whether these participants had suffered from adverse effects because no explanation is given by the authors. </p> <p><b>Sick days</b> </p> <p>In a change from protocol, we added 'sick days' as a secondary outcome because two studies included this measurement and because it is a complementary measurement of impairment due to Ménière's disease and can be related to quality of life. </p> <p>In the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> and <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> studies, sick days were described as days with an activity level of 3 or 4 (see above). <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> used the proportion of sick days for comparison across groups over a four‐month period. </p> </section> <section id="CD008419-sec-0074"> <h6 class="title">Other outcomes</h6> <p><a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> used the summated potential/action potential ratio of the electrocochleographic response complex as a primary outcome measure. A secondary outcome in this study was measurement of responses to low‐frequency burst stimulation. </p> <p><a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> compared the pretreatment electrocochleographic results between groups at two and four months follow‐up. </p> </section> <section id="CD008419-sec-0075"> <h6 class="title">Timing of outcome measurement</h6> <p>As stated in the protocol, we also considered studies with a shorter period of follow‐up than that advised by the AAO‐HNS (at least two years). There is only one study with a follow‐up duration of two years (<a href="./references#CD008419-bbs2-0025" title="GatesGA , VerrallA , GreenJD , TucciDL , TelianSA . Meniett clinical trial: long‐term follow up. Archives of Otolaryngology ‐‐ Head and Neck Surgery2006;132:1311‐6. ">Gates 2006</a>). This 2006 publication reports the longer‐term follow‐up of the participants reported by <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a>. </p> </section> </section> </section> <section id="CD008419-sec-0076"> <h4 class="title">Excluded studies</h4> <p>All excluded studies were non‐RCTs (<a href="./references#CD008419-bbs2-0006" title="BarbaraM , ConsagraC , MoniniS , NostroG , HarguindeyA , VestriA , et al. Local pressure protocol, including Meniett, in the treatment of Meniere's disease: short‐term results during the active stage. Acta Oto‐Laryngologica2001;121:939‐44. ">Barbara 2001</a>; <a href="./references#CD008419-bbs2-0007" title="BuchananM , RaiA , PrinsleyP . Initial UK experience of patient satisfaction with the Meniett device for Meniere's disease treatment. Journal of Laryngology and Otology2010;124:1067‐72. ">Buchanan 2010</a>; <a href="./references#CD008419-bbs2-0008" title="DensertB , SassK . Control of symptoms in patients with Ménière's disease using middle ear pressure applications: two year follow‐up. Acta Oto‐Laryngologica2001;121:616‐21. ">Densert 2001</a>; <a href="./references#CD008419-bbs2-0011" title="StokroosR , Klein OlvinkM , HendriceN , KingmaH . Functionality outcome of treatment of Meniere's disease with the Meniett pressure generator. Acta Oto‐Laryngologica2006;126:254‐8. ">Stokroos 2006</a>), compared the Meniett with another pressure pulse generator (<a href="./references#CD008419-bbs2-0009" title="FranzB . P‐100 in the treatment of Meniere's disease: a clinical study. International Tinnitus Journal2005;11:146‐9. ">Franz 2005</a>), or compared patients with Ménière's disease with delayed endolymphatic hydrops (<a href="./references#CD008419-bbs2-0010" title="ShojakuH , WatanabeY , MinetaH , AokiM , TsubotaM , WatanabeK , et al. Long‐term effects of the Meniett device in Japanese patients with Meniere's disease and delayed endolymphatic hydrops reported by the Middle Ear Pressure Treatment Research Group of Japan. Acta Oto‐Laryngologica2011;131:277‐83. ">Shojaku 2011</a>; <a href="./references#CD008419-bbs2-0012" title="WatanabeY , ShojakuH , JunichoM , AsaiM , FujisakaM , TakakuraH , et al. Intermittent pressure therapy of intractable Meniere's disease and delayed endolymphatic hydrops using the transtympanic membrane massage device: a preliminary report. Acta Oto‐Laryngologica2011;131:1178‐86. ">Watanabe 2011</a>). </p> </section> </section> <section id="CD008419-sec-0077"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias in the included studies is summarised in <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#FIG-02" target="_blank">Figure 2</a> and <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#FIG-03" target="_blank">Figure 3</a> and detailed descriptions are given in the text below. Three out of five studies were at overall low risk (<a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a>; <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a>; <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a>), the <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#STD-Densert-1997" target="_blank">Densert 1997</a> study was at unclear risk and the <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#STD-Odkvist-2000" target="_blank">Odkvist 2000</a> study was at high risk of bias. </p> <section id="CD008419-sec-0078"> <h4 class="title">Allocation</h4> <p>In the <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> study, no information is given about allocation sequence generation and concealment. There is also no information about the method of blinding. It is stated that patients in the placebo group received the same procedure, without stimulation of the ear. No power analysis was performed. </p> <p>In the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> study, the allocation sequence generation and concealment were adequate. All baseline characteristics between the active treatment group and the placebo group were comparable and no significant differences were reported between the two groups. Treatment group allocation was done using a randomised four‐patient block design based on gender and normal/abnormal pretreatment caloric test results (abnormal being patients with a 30% or greater canal weakness). The rationale for this method of randomisation was not given. The original sample size was set at 52 patients, but an interim power analysis suggested the need to increase the number by at least 10. It is unclear why an interim power analysis was performed and it is unclear what clinical significant effect was used in this calculation. </p> <p>In the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study, allocation sequence generation and concealment seemed adequate. All patients received a ventilation tube and it was stated that patients were randomly assigned to active treatment or placebo group. The method of randomisation was not described. Baseline characteristics of both groups were identical for age, sex, duration and severity of the disease and canal paresis. The power to detect a treatment difference was calculated as 80% (definite vertigo days, SD = 5, difference in means = 3, n = 70). A total of 74 patients were randomised, but six were later excluded. Excluded patients were only from the placebo group. </p> <p>The <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study was stated to be randomised, but no description is given of allocation sequence generation and concealment. It was stated that patients who were randomised to the placebo group received a similar‐looking device and identical instructions. There was also no description of randomisation or whether the physicians were also blinded. No power analysis was performed. </p> <p>In the <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> study, the allocation sequence generation and concealment are not adequately described. Only patients who had had at least two attacks in the two months before the pre‐trial period and in the pre‐trial period (after insertion of the ventilation tube) were included. In the actual trial they were randomised to active or placebo groups. The method of randomisation was not described. Baseline characteristics were identical in both groups for age, sex, length of history, severity of disease and degree of hearing loss. No power analysis was provided to account for the number of participants. </p> </section> <section id="CD008419-sec-0079"> <h4 class="title">Blinding</h4> <p>In the <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> study, it is stated that both investigators and patients were blinded, but the methods of blinding are not described. The placebo was a device that looked similar, but which gave no stimulation to the ear. In all patients a ventilation tube was inserted and patients in the placebo group received the same procedure but without pressure stimulation. </p> <p>In the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> study, the participants and investigators were blinded to the treatment used. The active and placebo devices were identical in appearance and both generated a similar clicking sound and light display. The devices were sealed to assure integrity. It is not stated whether the placebo device gave a slight pressure pulse. </p> <p>In the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study, it is stated that both participants and evaluators were blinded to the treatment assignments. The placebo device had identical acoustic properties to the Meniett device and produced only a slight pressure increase to 2 cm H<sub>2</sub>O. </p> <p>In the <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study, it is stated that both investigators and patients were blinded, but the methods of blinding are not described. Placebo was applied by a device that looked similar, but did not give stimulation to the ear. </p> <p>In the <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> study, it is stated that patients and investigators were blinded as to which type of apparatus was in use. The placebo device was visually identical to the active device but did not give any pressure pulses, except a slight pressure increase to 2 cm H<sub>2</sub>O for five seconds to maintain the leakage test. </p> </section> <section id="CD008419-sec-0080"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> gives no information about intention‐to‐treat analysis or loss of data. This study had an open design and it is not reported whether there were any excluded participants or drop‐outs. </p> <p><a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> reported an intention‐to‐treat analysis in the methods section of their article, stating that "data from participants failing before the end point were calculated as of their time of last follow‐up and carried forward for the entire follow‐up period". However, in the results section it is stated that two participants withdrew and three dropped out. The outcomes of these five patients were not carried forward to the endpoint. There were five treatment failures noted and, once again, it is stated that their data were carried forward to the endpoint, giving a total of 62 participant data sets to be evaluated. When the results are discussed, however, the total number of participants decreases over time (especially in the placebo group), resulting in a total of 57 participants at the four‐month follow‐up point. The reason for this is that data from failure cases were actually not included in the final analysis. This is a per‐protocol analysis, not intention‐to treat, contrary to what is claimed in the methods section. Furthermore, whether drop‐outs and treatment failures were patients in the active treatment group or placebo is not described. </p> <p>In the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study, 74 patients were randomised to active treatment or placebo. During follow‐up there was one drop‐out in the placebo group, with no reason given. In the Meniett group, five participants were excluded. In this group there was one drop‐out, without explanation. Three participants left the treatment because of lack of improvement and one participant was excluded because of lack of compliance. No intention‐to‐treat analysis was performed. </p> <p>In the <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study, no information is given about intention‐to‐treat analysis or loss of data. </p> <p><a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> stated that of the 63 participants who passed the entry criteria, 23 (36.5%) were later excluded because of "noncompliance with the treatment or study protocol." No further information on the reasons for exclusion was given. The number of excluded participants per treatment group was not given. No intention‐to‐treat analysis was performed. </p> </section> <section id="CD008419-sec-0081"> <h4 class="title">Selective reporting</h4> <p>No information was given about missing data in the <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> and <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> studies (see above). The data for the participants who were considered failures are not given in <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a>, nor in <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a>. </p> <p>In the <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> study, only mean scores and standard deviations are given for the electrocochleography results. For the measurements of vertigo, tinnitus and aural fulness no (statistical) data are provided. </p> <p>The numerical data for the total monthly vertigo score (mean and standard deviation) are not given in the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> study. Additionally, there are no numerical data, only proportions of days with vertigo, vertigo attacks and sick days. Without concrete mean and standard deviation data the results cannot be recalculated. The reason for using proportions is unclear. </p> <p>Descriptions of mean scores and standard deviations are given in the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study. </p> <p>In the <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study, the numerical data for the total monthly vertigo score (mean and standard deviation) are not given. Only one table is presented without a proper scale for the measurements. </p> <p>There are some questions regarding the statistical methods used when analysing the results. <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> described the methods of statistical analysis in detail, stating that the decrease in frequency of vertigo scores was recalculated in a ratio R (Ra or Rb) per treatment group. These ratios were compared to each other, giving a value T. A small T value indicates a beneficial effect of the A treatment compared to the B treatment. Strangely, when reviewing the results of the study, these T values are not given, but the results are given in means with standard deviations. The same goes for the visual analogue scale (VAS) score: a complex scoring system is described comparing individual VAS scores between patient A and patient B. The results of this scoring system are not given, however, as the results are given in means with standard deviations. </p> </section> <section id="CD008419-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <section id="CD008419-sec-0083"> <h5 class="title">Follow‐up</h5> <p>In the <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> study, there was only a direct evaluation after stimulation and no follow‐up. There are no reports of participants lost to follow‐up. </p> <p>The loss to follow‐up in <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> was 10 participants out of a total of 67 (14.9%). The reasons for the loss to follow‐up are well described, although the number of failures is asymmetrically distributed (one in the active group and four in the placebo group). </p> <p>The loss to follow‐up over four weeks in the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study was two patients out of 74; four were excluded. The loss to follow‐up (due to exclusion or drop‐out) was asymmetrically distributed (five in the active group versus one in the placebo group). Sixty‐eight participants were analysed (92%). A therapeutic effect of the slight pressure impulses of the placebo device cannot be excluded. </p> <p>In the <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study, no information was given about loss to follow‐up after two weeks. </p> <p>Follow‐up was eight weeks in the <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> study. A large number of participants (36.5%) were excluded, without adequate descriptions. </p> </section> <section id="CD008419-sec-0084"> <h5 class="title">Funding</h5> <p>No funding was declared by <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a>, <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> and <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a>. </p> <p>The study <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> was funded by the Medtronic Xomed company in all participating centres. Dr Gates, the main author of the article, served as a paid consultant to Medtronic Xomed at a scientific retreat in 2000. </p> <p>In the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study, no funding was declared. The Meniett devices were provided by Medtronic Xomed for the duration of the study. </p> </section> <section id="CD008419-sec-0085"> <h5 class="title">Grading: AAO‐HNS diagnosis</h5> <p>We graded all studies on a scale of I to III (for the grading system, see <a href="#CD008419-sec-0039">Types of participants</a>). The <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> study used the clinical criteria of the 1995 Committee on Hearing and Equilibrium and is therefore Grade I. <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> and <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> explicitly described the inclusion of patients with definite Ménière's disease using the AAO‐HNS criteria, therefore these studies are also Grade I. <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> did not explicitly mention the AAO‐HNS criteria, but the descriptions of the patients and symptoms are equal to the criteria, therefore it is also Grade I. In the <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study, the AAO‐HNS criteria are not mentioned and the article provides very few details about the inclusion criteria, therefore it is Grade III. </p> </section> <section id="CD008419-sec-0086"> <h5 class="title">Grading: AAO‐HNS outcome measurement</h5> <p>The AAO‐HNS Committee on Hearing and Equilibrium describes clear measurement of 'control of vertigo'. The number of vertigo attacks in the interval between 18 to 24 months after treatment (y) is divided by the number of vertigo spells for the period of six months prior to the treatment (x) and multiplied by 100. The resulting number indicates the extent of 'control of vertigo'. None of the included studies used a follow‐up period longer than four months, therefore none contain high‐quality outcome measurements. </p> <p>All studies used vertigo as a primary outcome measure but in different ways. <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> and <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> measured this in the same manner, by using a Likert scale of the severity of vertigo attacks (see also <a href="#CD008419-sec-0041">Types of outcome measures</a>). <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> used the frequency of vertigo attacks and VAS scores. <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> and <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> only used VAS scores for measuring vertigo. </p> </section> </section> </section> <section id="CD008419-sec-0087"> <h3 class="title" id="CD008419-sec-0087">Effects of interventions</h3> <p>See: <a href="./full#CD008419-tbl-0001"><b>Summary of findings for the main comparison</b> Positive pressure therapy versus placebo for Ménière's disease or syndrome</a> </p> <section id="CD008419-sec-0088"> <h4 class="title">Positive pressure therapy versus placebo</h4> <section id="CD008419-sec-0089"> <h5 class="title">Primary outcome</h5> <section id="CD008419-sec-0090"> <h6 class="title">Control of vertigo or decrease in vertigo attacks</h6> <p>As all included studies used different measurements for vertigo, it was not possible to combine the data in a meta‐analysis. </p> <p>In the <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> study, no exact data are given, therefore this study cannot be used in any analysis. In this study, it was stated that subjective symptoms of vertigo, measured with visual analogue scales (VAS), did not significantly change in the active treatment group or in the placebo group. Transient aggravation of vertigo upon first use of the device was also not present. No exact data or statistical analyses are available in the article. </p> <p><a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> used vertigo scores (see <a href="#CD008419-sec-0060">Included studies</a>) at one, two, three and four months and the proportion of vertigo days in four months. The report describes a decrease in the total monthly definitive vertigo scores in the active group and in the control group. The results are given in a figure, which illustrates that the decrease in total monthly vertigo score is greater in the active group. No numerical data, means or standard deviations were given. The difference was greatest at the time points of one, two and three months and smallest at the four‐month time point. According to the authors, an ANOVA repeated measures analysis with total definitive vertigo score as the dependent variable showed that the difference was significant (P value = 0.03), with treatment group and treatment months as the predictor variables. There was a decrease in the proportion of days with definite vertigo in both the placebo group and treatment group. This decrease was not significant at any time point and neither was the difference between groups at any time point. In the placebo group, the proportion of days with definitive vertigo decreased from a mean of 0.24 (standard deviation (SD) 0.22) at baseline to 0.11 (SD 0.16) after four months of follow‐up. In the active group, the proportion of days with vertigo decreased from 0.20 (SD 0.17) at baseline to 0.10 (SD 0.14) after four months of follow‐up. The mean difference between the groups after four weeks of treatment was ‐0.01 (95% confidence interval (CI) ‐0.08 to 0.06, overall effect Z = 0.26, P value = 0.79) (<a href="./references#CD008419-fig-0004" title="">Analysis 1.1</a>). With a multiple linear regression analysis of the cumulative four‐month proportion of days with definite vertigo as a dependent variable and vertigo at baseline as predictor variable, significant results were found (coefficient 0.226, P value = 0.03). </p> <p>In the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study, there was a significant decrease in cumulative vertigo scores over a four‐month period in the active treatment group (pre‐ and post‐treatment values 22.47 to 15.97) and the placebo group (20.42 to 19.23). The treatment effect (expressed as the difference between the pre‐treatment and post‐treatment vertigo score) was 6.5 for the active treatment group and 1.19 for the placebo group, which was significant (P value = 0.048). The mean difference (MD) for vertigo scores after four months in our analysis was ‐3.68 (95% CI ‐14.24 to 6.88) (<a href="./references#CD008419-fig-0005" title="">Analysis 1.2</a>). This is a non‐significant difference (P value = 0.49). In the active treatment group there was a decline in vertigo scores in the first two months and a slight increase in the third month, followed by a decrease in the fourth month. In the placebo group, there was an increase in vertigo in the first month and in the fourth month. There are no statistical analyses available per month and no exact data are available over the different follow‐up periods in the article, but Dr Gurkov provided us with raw data. There is also no explanation given by the authors for this attrition or the differences between the active and placebo groups. For vertigo days, no significant difference was found in the active group (6.5 to 4.08) or in the placebo group (5.94 to 5.52) (P value = 0.10). The mean difference (MD) between the groups was ‐1.55 (95% CI ‐5.40 to 2.30), which was not significant (P value = 0.43) (<a href="./references#CD008419-fig-0006" title="">Analysis 1.3</a>). </p> <p>In <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a>, no exact data are given, therefore this study cannot be used in any analysis. In this study, the authors reported a significant improvement in vertigo scores in the active treatment group, established with visual analogue scales. There is no explanation available of the range of the scale, nor of the numbers in the figure, and no baseline figures or P values are reported. In the statistical analysis section, it is stated that student t‐tests are used, but no exact data are described. Additionally, the meaning of the negative numbers in the placebo group is unclear: in the active group the score is 4.55, in the placebo group ‐0.64. We have not been able to recalculate this number due to a lack of statistical data. </p> <p><a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> used the frequency of vertigo and VAS scores for vertigo, comparing the eight weeks before treatment to the last four weeks of treatment (a total of eight weeks of treatment). In this study, there was a decrease in the frequency of vertigo in the active group from 9.6 (6.7) in the eight weeks before treatment to 1.9 (4.1) in the last four weeks of treatment. The placebo group had a vertigo frequency of 10.5 (8.2) in the eight weeks before treatment compared to 4.0 (5.9) in the last four weeks of treatment (numbers given in mean (SD)). The difference in the frequency of vertigo between the four weeks before treatment compared to the last eight weeks of treatment was significantly decreased in both groups (although this was not mentioned in the article). The MD in vertigo score in the last four weeks of treatment was ‐2.10 (95% CI ‐5.25 to 1.05) (<a href="./references#CD008419-fig-0007" title="">Analysis 1.4</a>). The difference <i>between</i> the two groups was not significant (P value = 0.19). There was a statistically significant decrease in total VAS score in both groups after treatment, with the greatest reduction in the treatment group. In the treatment group, VAS scores reduced from 67.3 (21.7) to 25.5 (20.5) and in the placebo group from 64.9 (22.4) to 46.6 (25.6) (P value = 0.005). The MD in our analysis was ‐21.10 (95% CI ‐35.47 to ‐6.73) (<a href="./references#CD008419-fig-0008" title="">Analysis 1.5</a>), with a significant overall effect favouring the Meniett group (P value = 0.004). </p> </section> </section> <section id="CD008419-sec-0091"> <h5 class="title">Secondary outcomes</h5> <section id="CD008419-sec-0092"> <h6 class="title">Loss or gain of hearing</h6> <p>Pooled analysis of <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#STD-Gates-2004" target="_blank">Gates 2004</a> and <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#STD-Gurkov-2012" target="_blank">Gurkov 2012</a> showed a statistically significant hearing gain (MD 7.38 dB, 95% CI 2.51 to 12.25, overall effect P value = 0.003, Chi<sup>2</sup> = 0.10, df = 1 (P value = 0.76); I² = 0%) in favour of the placebo group compared to the Meniett group. We used a fixed‐effect model (<a href="./references#CD008419-fig-0009" title="">Analysis 1.6</a>). The average low‐frequency (0.25 kHz, 0.5 kHz, 1 kHz) pure‐tone thresholds were lower in the placebo group compared to the active treatment group after treatment, meaning hearing improvement in the placebo group. Both studies combined showed a lower mean hearing threshold in the placebo group after treatment, but in the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> study, there was an improvement in hearing found in both groups, while in the <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study a slight deterioration in hearing levels was found. </p> <section id="CD008419-sec-0093"> <p><b>Analysis per study</b></p> <p><a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> described no change in hearing thresholds following treatment either within or between groups, but the mean low‐frequency hearing thresholds in the active treatment group were 51.9 (23.4) and in the placebo group 42.7 (25.6). </p> <p><a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> found a slight hearing loss in both groups. In the active treatment group the difference between pre‐ and post‐treatment hearing thresholds increased from 53.18 to 49.15 dB at 1000 Hz and in the placebo group from 46.10 to 41.66 dB. These differences were not significant between groups (P value = 0.881). </p> <p>In the <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study, hearing improvement was found in some patients in the active treatment group, but not in the placebo group. The mean improvement was 4 dB for the 500 Hz, 5 dB for the 1000 Hz and 3 dB for the 2000 Hz frequency. Significant differences between pre‐ and post‐treatment were found at the frequencies of 500 Hz (P value &lt; 0.03) and 1000 Hz (P value &lt; 0.01). The mean difference in hearing threshold levels pre‐ and post‐treatment in the placebo group did not differ significantly at any frequency. No exact data are provided. </p> <p><a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> stated that there was no difference in VAS perception of hearing between the study groups. No exact data are provided. </p> </section> </section> <section id="CD008419-sec-0094"> <h6 class="title">Severity of tinnitus</h6> <p>In the <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> study, results of measurements of tinnitus are given but without any explanation or standard deviations. A difference was shown between the active treatment group (2.52) and the placebo group (‐1.6). The other studies either did not include tinnitus (<a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a>; <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a>), or no exact data are given (<a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a>; <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a>). </p> </section> <section id="CD008419-sec-0095"> <h6 class="title">Perception of aural fullness</h6> <p>Aural fullness is not measured in the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> and <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> studies and no exact data are given in the <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a>, <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a> and <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> studies. </p> </section> <section id="CD008419-sec-0096"> <h6 class="title">Functional level</h6> <p>Pooled meta‐analysis for activity/functional level scores after treatment was not possible, due to the use of different measurements in the included studies. </p> <section id="CD008419-sec-0097"> <p><b>Analysis per study</b></p> <p>In the <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#STD-Gurkov-2012" target="_blank">Gurkov 2012</a> study, the cumulative activity score decreased by 10.19 (SD 17.73) in the active treatment group and 4.45 (SD 15.8) in the placebo group. At the endpoint the activity score was 13.05 (SD 17.04) in the active treatment group and 20.23 (SD 25.44) in the placebo group. The treatment effect was not significantly greater in the active treatment group (P value = 0.08). There was no significant difference found between the two groups (z = 1.34, P value = 0.18) (<a href="./references#CD008419-fig-0010" title="">Analysis 1.7</a>). </p> <p>In the <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#STD-Thomsen-2005" target="_blank">Thomsen 2005</a> study, there was a decrease in functional level score in both groups when comparing pre‐ and post‐treatment scores. This means better functional ability (i.e. less impairment). The decrease was significant in the treatment group (decrease from 4.2 to 2.4) compared to the placebo group (decrease from 4.1 to 3.5) (AAO‐HNS criteria, one‐ to six‐point scale: MD ‐1.10, 95% CI ‐1.81 to ‐0.39, z = 3.02, P value = 0.003) (<a href="./references#CD008419-fig-0011" title="">Analysis 1.8</a>). </p> <p>In the <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#STD-Odkvist-2000" target="_blank">Odkvist 2000</a> study, it was stated that the functionality profile changed in the active treatment group (3.48) versus the placebo group (‐0.2), but no explanation of these numbers or standard deviations were given. </p> </section> </section> <section id="CD008419-sec-0098"> <h6 class="title">Complications and adverse events</h6> <p>None of the included studies reported complications or adverse events.</p> <p>There were no reports of acute vertigo immediately after the first use of the device (<a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a>), which can be interpreted as absence of (immediate) adverse events. </p> </section> <section id="CD008419-sec-0099"> <h6 class="title">Sick days</h6> <p>Pooled analysis of sick days, measured in the <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#STD-Gates-2004" target="_blank">Gates 2004</a> and <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#STD-Gurkov-2012" target="_blank">Gurkov 2012</a> studies, did not show a statistically significant effect (MD ‐1.03, 95% CI ‐3.59 to 1.53, overall effect P value = 0.43 with Tau² = 2.77; Chi² = 4.28, df = 1 (P value = 0.04); I² = 77%). We used a random‐effects model (<a href="./references#CD008419-fig-0012" title="">Analysis 1.9</a>). </p> <section id="CD008419-sec-0100"> <p><b>Analysis per study</b></p> <p>In the <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#STD-Gates-2004" target="_blank">Gates 2004</a> study, there was a decrease in the proportion of sick days in both the placebo group and the active group. This decrease was not significant within groups or between groups at any time point. The proportion of sick days after four months of treatment was 0.01 (SD 0.02) in the active treatment group and 0.01 (SD 0.02) in the placebo group, with a mean difference of 0.00 (95% Cl ‐0.01 to 0.01). </p> <p>In the <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#STD-Gurkov-2012" target="_blank">Gurkov 2012</a> study, the mean number of sick days decreased from 3.08 to 0.78 in the active treatment group and increased from 2.87 to 3.45 in the placebo group, with a significant treatment effect in the active treatment group (P value = 0.04). We calculated a mean number of sick days in the intervention group of 0.76 (SD 1.61) and 3.45 (SD 7.09) in the placebo group after four months of treatment. The mean difference in our analysis was ‐2.69 (95% Cl ‐5.24 to ‐0.14), favouring the Meniett (<a href="./references#CD008419-fig-0012" title="">Analysis 1.9</a>). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008419-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008419-sec-0101"></div> <section id="CD008419-sec-0102"> <h3 class="title" id="CD008419-sec-0102">Summary of main results</h3> <p>There is no high‐quality evidence of an effect of positive pressure therapy in Ménière's disease. No included studies specifically described the results of treatment in patients with Ménière's syndrome. </p> <p>Although two of our included studies had an overall low risk of methodological bias (assessed using the Cochrane 'Risk of bias' tool), the lack of homogeneity in the outcome measures used made it inappropriate to combine results for our primary outcome, control of vertigo or decrease in vertigo attacks, in either a meta‐analysis or sensitivity analysis. Vertigo frequency, vertigo scores after four months, vertigo days in four months and proportion of vertigo in four weeks did not show significant results (<a href="./references#CD008419-fig-0004" title="">Analysis 1.1</a>; <a href="./references#CD008419-fig-0005" title="">Analysis 1.2</a>; <a href="./references#CD008419-fig-0006" title="">Analysis 1.3</a>; <a href="./references#CD008419-fig-0007" title="">Analysis 1.4</a>). Only one significant difference was found in one study, using visual analogue scale (VAS) scores for vertigo, favouring the Meniett® device (<a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a>; <a href="./references#CD008419-fig-0008" title="">Analysis 1.5</a>). The clinical relevance of the results found is uncertain. </p> <p>We carried out pooled meta‐analyses for some of our secondary outcomes (loss or gain of hearing and sick days), which included two studies per analysis. We found significant results only for loss or gain of hearing (<a href="./references#CD008419-fig-0009" title="">Analysis 1.6</a>). The average low‐frequency (0.25 kHz, 0.5 kHz, 1 kHz) pure‐tone thresholds were lower in the placebo group compared to the active treatment group after treatment. This means that the hearing loss was greater in the Meniett group. However, when compared to baseline levels, one study found an overall increase of hearing level, while the other showed a slight deterioration of hearing levels. </p> <p>It was not possible to use pooled data for the secondary outcome measure, functional level, due to heterogeneity in the outcome measures. One study did not show significant differences between the groups (<a href="./references#CD008419-fig-0010" title="">Analysis 1.7</a>). Only one included study showed a significantly lower functional level (less reduction in activities) in the Meniett group compared to the placebo group (<a href="./references#CD008419-fig-0011" title="">Analysis 1.8</a>). We found non‐significant differences between the two groups in the number of sick days after treatment (<a href="./references#CD008419-fig-0012" title="">Analysis 1.9</a>). </p> <p>No statistical data were available from the included studies for severity of tinnitus or perception of aural fullness. </p> <p>No adverse effects or complications were reported in the included studies. It is stated that the Meniett device in itself is a minimally invasive device. However, a tympanostomy tube has to be inserted, with the associated risks of anaesthesia and the risks of (any) surgery such as infection and bleeding. A risk of otorrhoea and tympanosclerosis is also associated with the insertion of a tympanostomy tube. </p> <p>In summary, there is insufficient good evidence of an effect of the Meniett device on vertigo. For the secondary outcome measures, we found inconclusive results for hearing loss and functional level. Hearing loss seems to be greater after using the Meniett compared to placebo. There is no evidence of improvement in vertigo, tinnitus, aural fullness or sick days. </p> </section> <section id="CD008419-sec-0103"> <h3 class="title" id="CD008419-sec-0103">Overall completeness and applicability of evidence</h3> <p>The evidence is currently insufficient to answer the review question: what are the effects of positive pressure therapy compared to placebo, in terms of vertigo, loss or gain of hearing, severity of tinnitus, severity of aural fullness, functional level and sick days in patients with Ménière's disease? We only included five studies in this review and we considered three of them to have an unclear or high risk of bias. Additionally, due to clinical diversity in the measurement of vertigo, it was not possible to perform a meta‐analysis for this primary outcome measure. This limits the completeness of the evidence relevant to this review. The lack of sufficient high‐quality evidence, and the absence of statistical meta‐analysis for control of vertigo, makes it inappropriate to draw conclusions from the results regarding the applicability of positive pressure therapy for patients within the context of current practice in Ménière's disease. </p> </section> <section id="CD008419-sec-0104"> <h3 class="title" id="CD008419-sec-0104">Quality of the evidence</h3> <p>None of the five included studies used the American Academy of Otolaryngology ‐ Head and Neck Surgery (AAO‐HNS) criteria for 'control of vertigo'. Additionally, none of the studies use long‐term follow‐up as advised by the AAO‐HNS. </p> <p>Of the five included studies, we considered only three to have low risk of bias; the other two studies are at unclear and high risk of bias (<a href="#CD008419-fig-0002">Figure 2</a>; <a href="#CD008419-fig-0003">Figure 3</a>). All studies are reasonably consistent in their findings, showing only positive results for sub‐analyses. No adverse effects were reported. Some comments can be made about the studies concerning the quality of the evidence (see also <a href="./full#CD008419-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>The <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> study is adequately set up with good allocation, blinding and randomisation. There are some questions, however, about the analysis of the results. First of all, the authors use a per‐protocol analysis (while claiming to use an intention‐to‐treat analysis) when evaluating the efficacy of therapy. In doing so, we feel that the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> study overestimates the effect of the placebo device (and underestimates the effect of the Meniett device), because most treatment failures dropped out of the placebo group. The decrease in days with vertigo is not significantly different in the treatment group compared to the placebo group in any of the follow‐up months. A large number of statistical calculations are presented in this study (namely ANOVA) with a number of statistically significant outcomes. However, in our opinion, the most important and clinically relevant finding of this study is the fact that there is no statistical difference in the number of vertigo days between the two groups. Also, due to the summation of categorical variables, the results are unclear. There is no reported attempt to validate whether two days of grade 3 vertigo is clinically equivalent to three days with grade 2 vertigo. Additionally, participants had a low‐sodium diet and a high proportion were using diuretics. </p> <p>The <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a> study is adequately set up with good allocation, blinding and randomisation. Selective reporting bias is unclear in the article, because all data are presented as mean difference, without exact means and standard deviations at each time point. However, Dr Gurkov supplied us with exact data for the study, allowing us to calculate means and standard deviations. Only the total vertigo score differed significantly between the active treatment and placebo group; definite vertigo days and vertigo‐free days did not differ between groups. Most drop‐outs were in the placebo group, as in the <a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a> study. These drop‐outs are not characterised and are left out of the statistical analysis, therefore there is no intention‐to‐treat‐analysis. Although the study included four follow‐up measurements, no differences between follow‐up periods are presented. Additionally, there are no explanations given for the increase in vertigo scores after the third month of treatment in the active treatment group. In this study, betahistine was given additionally to the Meniett device. The authors concluded that a smaller overall treatment effect may be partially due to this additional treatment. We feel that the contribution of betahistine to the Meniett patients is unclear, as all patients were characterised as unresponsive to betahistine. </p> <p>In the <a href="./references#CD008419-bbs2-0005" title="ThomsenJ , SassK , OdkvistL , ArlingerS . Local overpressure treatment reduces vestibular symptoms in patients with Ménière's disease: a clinical, randomised, multicenter, double‐blind, placebo‐controlled study. Otology &amp; Neurotology2005;26(1):68‐73. [PUBMED: 15699722] ">Thomsen 2005</a> study, the method of randomisation was not reported and only patients with at least two vertigo attacks in the two months after the insertion of a ventilation tube were selected. The study included somewhat non‐transparent and complicated statistical results and was incompletely reported. Twenty‐three patients were excluded because of non‐compliance with the treatment or study protocol. There is no explanation of why these patients were non‐compliant or to which group they were randomised. Due to this exclusion, no intention‐to‐treat analysis is possible. It is also unclear why the authors used the frequency of vertigo attacks in the two months before the insertion of the ventilation tube and not the frequency in the two months after the insertion of the ventilation tube, although it is stated that this is supposed to rule out the effect of the ventilation tube. A Monte Carlo statistical technique was used for analysis, although it is unclear why this technique was used. In this study, the vertigo attacks did not differ significantly between the active treatment group and the placebo group, but a significant improvement in VAS scores was found. It is not stated by the authors whether there was also a significant improvement in the placebo group following treatment. </p> <p>For the studies of <a href="./references#CD008419-bbs2-0001" title="DensertB , DensertO , ArlingerS , SassK , OdkvistL . Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière's disease: a clinical placebo‐controlled study. American Journal of Otology1997;18:726‐33. ">Densert 1997</a> and <a href="./references#CD008419-bbs2-0004" title="OdkvistLM , ArlingerS , BillermarkE , DensertB , LindholmS , WallqvistJ . Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's Disease ‐ a clinical multicentre placebo‐controlled study. Acta Oto‐Laryngologica. Supplement2000;543:99‐101. ">Odkvist 2000</a>, inadequate or unclear description of allocation, blinding and randomisation, as well as unclear reporting bias affect the quality of their findings. However, these studies found similar results to the other studies. </p> </section> <section id="CD008419-sec-0105"> <h3 class="title" id="CD008419-sec-0105">Potential biases in the review process</h3> <p>We used an extensive search strategy, which included more than 14 databases and was subject to no language or publication restrictions, to capture all trials relevant to this review, both published and unpublished. It is unlikely that any relevant study has been missed in this review. We additionally scanned published reviews on positive pressure therapy for Ménière's disease (<a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#REF-Medtronic-ENT" target="_blank">Medtronic ENT</a>; <a href="http://archie.cochrane.org/sections/documents/viewDiff?documentPK=66F5A8D782E26AA20133FE5D2A8660C5%26versionPK1=z1307221415590904362989567211491%26versionPK2=z1310141209469298465421670835995#REF-NHS-2012" target="_blank">NHS 2012</a>), but did not find further references. We were able to contact the primary investigators of two included studies for additional data and information (<a href="./references#CD008419-bbs2-0002" title="GatesGA , GreenJDJr , TucciDL , TelianSA . The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Archives of Otolaryngology ‐‐ Head and Neck Surgery2004;130(6):718‐25. [PUBMED: 15210552] ">Gates 2004</a>; <a href="./references#CD008419-bbs2-0003" title="GurkovR , Filipe MingasLB , RaderT , LouzaJ , OlzowyB , KrauseE . Effects of transtympanic low‐pressure therapy in patients with unilateral Ménière's disease unresponsive to betahistine: a randomised, placebo‐controlled, double‐blind, clinical trial. Journal of Laryngology &amp; Otology2012;126:356‐62. ">Gurkov 2012</a>). We could not reach the other authors. We also contacted Medtronic for additional, ongoing studies, but have not received a reply. </p> <p>We are not aware of any other potential biases in the review process.</p> </section> <section id="CD008419-sec-0106"> <h3 class="title" id="CD008419-sec-0106">Agreements and disagreements with other studies or reviews</h3> <p>A recent meta‐analysis has described significant reductions in vertigo with the Meniett device (<a href="./references#CD008419-bbs2-0014" title="AhsanSF , StandringRT . Meta‐analysis of Meniett therapy for Meniere's disease. Otolaryngology ‐ Head and Neck Surgery2013;149(2 Suppl):P105. ">Ahsan 2013</a>), which we cannot confirm in our review. For vertigo scores, the authors performed only qualitative analysis for individual studies. Taking in consideration the quality of the studies and the heterogeneity in the measurement of outcome measures in the different studies, we are more restrained in our conclusions compared to this review. As in our review, data for functional score could not be combined. No significant effects were found on pure‐tone average (PTA) pre‐ and post‐Meniett application. Additionally, we found significantly lower thresholds for hearing levels in the placebo group. Interestingly, Ashan et al also used prospective, retrospective and cross‐sectional/unknown types of studies, which we did not include in our review. Additionally, we did not only investigate the results in the Meniett groups of the included studies, but compared these with the placebo groups for a more complete review. </p> <p>A review of micro‐pressure therapy for refractory Ménière's disease was performed by the UK National Institute of Health Research (NIHR) in April 2012 (<a href="./references#CD008419-bbs2-0041" title="Meniett low‐pressure pulse generator (Medtronic ENT) for treatment of Meniere's disease. Healthcare Technology Brief Publication. Lansdale: HAYES, Inc2012. ">NHS 2012</a>). This review also included non‐randomised clinical trials. Nevertheless, our findings are comparable with the conclusions described in this review. The same randomised controlled trials (RCTs) were included as in this review. Case series suggested positive results for vertigo, functionality profile and hearing. However, in the NIHR review two case series reported middle ear infections and immediate postoperative ear discharge in seven out of 74 patients, although the included RCTs did not report adverse effects or complications. </p> <p>Medtronic has published an independent review of the Meniett pressure pulse generator and included the same RCTs as in this review (<a href="./references#CD008419-bbs2-0036" title="Treatment of Meniere's disease with the Meniett low‐pressure pulse generator. An independent clinical studies review for Medtronic ENT. http://www.medtronic.com/wcm/groups/mdtcom_sg/@mdt/@ent/documents/documents/ent‐article_summary.pdf2012. ">Medtronic ENT</a>). Additionally, two case series studies and one retrospective study were also included. These three studies included a total of 59 patients. Their review suggested positive effects on vertigo, nausea and aural fullness, whereas tinnitus and hearing remained unchanged. In one study, two patients out of 10 had to be treated for otorrhoea. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008419-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Process for sifting search results and selecting studies for inclusion." data-id="CD008419-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Process for sifting search results and selecting studies for inclusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008419-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD008419-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008419-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008419-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008419-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Positive pressure therapy versus placebo, Outcome 1 Proportion of days with vertigo in 4 weeks: vertigo scores &gt; 2." data-id="CD008419-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Positive pressure therapy versus placebo, Outcome 1 Proportion of days with vertigo in 4 weeks: vertigo scores &gt; 2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#CD008419-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008419-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Positive pressure therapy versus placebo, Outcome 2 Vertigo scores after 4 months." data-id="CD008419-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Positive pressure therapy versus placebo, Outcome 2 Vertigo scores after 4 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#CD008419-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008419-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Positive pressure therapy versus placebo, Outcome 3 Vertigo days in 4 months: vertigo scores &gt; 2." data-id="CD008419-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Positive pressure therapy versus placebo, Outcome 3 Vertigo days in 4 months: vertigo scores &gt; 2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#CD008419-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008419-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Positive pressure therapy versus placebo, Outcome 4 Vertigo frequency in the 8 weeks before and after 4 weeks of treatment." data-id="CD008419-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Positive pressure therapy versus placebo, Outcome 4 Vertigo frequency in the 8 weeks before and after 4 weeks of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#CD008419-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008419-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Positive pressure therapy versus placebo, Outcome 5 VAS scores for vertigo after 8 weeks of treatment." data-id="CD008419-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Positive pressure therapy versus placebo, Outcome 5 VAS scores for vertigo after 8 weeks of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#CD008419-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008419-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Positive pressure therapy versus placebo, Outcome 6 Loss or gain of hearing in 4 months (dB)." data-id="CD008419-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Positive pressure therapy versus placebo, Outcome 6 Loss or gain of hearing in 4 months (dB). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#CD008419-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008419-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Positive pressure therapy versus placebo, Outcome 7 Cumulative activity score at 4 months." data-id="CD008419-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Positive pressure therapy versus placebo, Outcome 7 Cumulative activity score at 4 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#CD008419-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008419-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Positive pressure therapy versus placebo, Outcome 8 Change in functional profile between 8 weeks before and after 4 weeks of treatment." data-id="CD008419-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Positive pressure therapy versus placebo, Outcome 8 Change in functional profile between 8 weeks before and after 4 weeks of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#CD008419-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008419-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/urn:x-wiley:14651858:media:CD008419:CD008419-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_t/tCD008419-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Positive pressure therapy versus placebo, Outcome 9 Sick days in 4 months." data-id="CD008419-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Positive pressure therapy versus placebo, Outcome 9 Sick days in 4 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#CD008419-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/media/CDSR/CD008419/image_n/nCD008419-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008419-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Positive pressure therapy versus placebo for Ménière's disease or syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Positive pressure therapy versus placebo for Ménière's disease or syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with Ménière's disease or syndrome<br/> <b>Settings:</b> ENT departments<br/> <b>Intervention:</b> positive pressure therapy versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Positive pressure therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of days with vertigo in 4 weeks: vertigo scores &gt; 2</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean proportion of days with vertigo in 4 weeks (vertigo scores &gt; 2) in the control groups was<br/> <b>0.11</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean proportion of days with vertigo in 4 weeks (vertigo scores &gt; 2) in the intervention groups was<br/> <b>0.01 lower</b> <br/> (0.08 lower to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cumulative vertigo scores after 4 months</b> <br/> Follow‐up: mean 4 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cumulative vertigo score after 4 months in the control groups was<br/> <b>19.23</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cumulative vertigo score after 4 months in the intervention groups was<br/> <b>3.68 lower</b> <br/> (14.24 lower to 6.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vertigo days in 4 months: vertigo scores &gt; 2</b> <br/> Follow‐up: mean 4 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo days in 4 months (vertigo scores &gt; 2) in the control groups was<br/> <b>5.52</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo days in 4 months (vertigo scores &gt; 2) in the intervention groups was<br/> <b>1.55 lower</b> <br/> (5.4 lower to 2.3 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vertigo frequency in the 8 weeks before and after 4 weeks of treatment</b> <br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo frequency in the 8 weeks before and after 4 weeks of treatment in the control groups was<br/> <b>4.0</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean vertigo frequency in the 8 weeks before and after 4 weeks of treatment in the intervention groups was<br/> <b>2.10 lower</b> <br/> (5.25 lower to 1.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VAS scores for vertigo after 8 weeks of treatment</b> <br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score for vertigo after 8 weeks of treatment in the control groups was<br/> <b>46.6</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score for vertigo after 8 weeks of treatment in the intervention groups was<br/> <b>21.1 lower</b> <br/> (35.47 to 6.73 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Loss or gain of hearing in 4 months (dB)</b> </p> <p>Follow‐up: mean 4 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hearing threshold at 0.25 kHz to 1 kHz in 4 months in the control groups was<br/> <b>44.4</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean loss or gain of hearing in 4 months in the intervention groups was<br/> <b>7.38 higher</b> <br/> (2.51 to 12.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cumulative activity score</b> </p> <p>Follow‐up: mean 4 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean activity score after 4 months in the control group was</p> <p><b>20.23</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cumulative activity score in the intervention groups was<br/> <b>7.18 lower</b> <br/> (17.68 lower to 3.32 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in functional profile in the 8 weeks before and after 4 weeks of treatment</b> </p> <p>Follow‐up: mean 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in functional profile in the 8 weeks before and after 4 weeks of treatment in the control group was <br/> <b>3.5</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in functional profile in the 8 weeks before and after 4 weeks of treatment in the intervention group was<br/> <b>1.10 lower</b> <br/> (1.81 to 0.39 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,8,9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sick days in 4 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sick days in 4 months in the control groups was<br/> <b>1.73</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sick days in 4 months in the intervention groups was<br/> <b>1.03 lower</b> <br/> (3.59 lower to 1.53 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3,4,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Per‐protocol analysis while claiming an intention‐to‐treat analysis.<br/> <sup>2</sup>No description of reasons for drop‐out or treatment failure.<br/> <sup>3</sup>Overestimation of the effect of the placebo device (and underestimation of the effect of the Meniett device), because most treatment failures dropped out of the placebo group.<br/> <sup>4</sup>The decrease in days with vertigo is not significantly different in the treatment group compared to the placebo group in any of the follow‐up months.<br/> <sup>5</sup>Additional low‐sodium diet.<br/> <sup>6</sup>A high proportion of participants used diuretics (80% in the placebo group and 73% in the active treatment group).<br/> <sup>7</sup>Additional use of betahistine.<br/> <sup>8</sup>Unclear statistics.<br/> <sup>9</sup>Use of frequencies before insertion of the ventilation tube and after treatment, while claiming to rule out the effect of the ventilation tube. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Positive pressure therapy versus placebo for Ménière's disease or syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008419-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane 'Risk of bias' tool</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Domain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Review authors' judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was the allocation sequence adequately generated?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was allocation adequately concealed?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinding of participants, personnel and outcome assessors</b> <br/> <i>Assessments should be made for each main outcome (or class of outcomes)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was knowledge of the allocated intervention adequately prevented during the study?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incomplete outcome data</b> <br/> <i>Assessments should be made for each main outcome (or class of outcomes)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomised participants), reasons for attrition/exclusions where reported, and any re‐inclusions in analyses performed by the review authors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Were incomplete outcome data adequately addressed?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selective outcome reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>State how the possibility of selective outcome reporting was examined by the review authors and what was found </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Are reports of the study free of suggestion of selective outcome reporting?</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane 'Risk of bias' tool</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/full#CD008419-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008419-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Positive pressure therapy versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of days with vertigo in 4 weeks: vertigo scores &gt; 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.08, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Vertigo scores after 4 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.68 [‐14.24, 6.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Vertigo days in 4 months: vertigo scores &gt; 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.55 [‐5.40, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Vertigo frequency in the 8 weeks before and after 4 weeks of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.1 [‐5.25, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 VAS scores for vertigo after 8 weeks of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐21.1 [‐35.47, ‐6.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Loss or gain of hearing in 4 months (dB) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.38 [2.51, 12.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Cumulative activity score at 4 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.18 [‐17.68, 3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change in functional profile between 8 weeks before and after 4 weeks of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.1 [‐1.81, ‐0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Sick days in 4 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.03 [‐3.59, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Positive pressure therapy versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008419.pub2/references#CD008419-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008419.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008419-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008419-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008419-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008419-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008419-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008419-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008419\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008419\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008419\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008419\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008419\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008419.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008419.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008419.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008419.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008419.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724832082"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008419.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724832086"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008419.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6c6e1f51f4ca',t:'MTc0MDcyNDgzMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 